<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">40474</article-id><article-id pub-id-type="doi">10.7554/eLife.40474</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>RalB directly triggers invasion downstream Ras by mobilizing the Wave complex</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-109246"><name><surname>Zago</surname><given-names>Giulia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8280-1589</contrib-id><email>giulia.zago@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109247"><name><surname>Veith</surname><given-names>Irina</given-names></name><email>irina.veith@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109249"><name><surname>Singh</surname><given-names>Manish Kumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118656"><name><surname>Fuhrmann</surname><given-names>Laetitia</given-names></name><email>Laetitia.fuhrmann@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-87537"><name><surname>De Beco</surname><given-names>Simon</given-names></name><email>simon.de-beco@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109248"><name><surname>Remorino</surname><given-names>Amanda</given-names></name><email>a.remorino@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109250"><name><surname>Takaoka</surname><given-names>Saori</given-names></name><email>saorid6e9p6p9@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118657"><name><surname>Palmeri</surname><given-names>Marjorie</given-names></name><email>marjorie_palmeri@alumni.brown.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118658"><name><surname>Berger</surname><given-names>Frédérique</given-names></name><email>frederique.berger@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118659"><name><surname>Brandon</surname><given-names>Nathalie</given-names></name><email>Nathalie.Brandon@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109251"><name><surname>El Marjou</surname><given-names>Ahmed</given-names></name><email>ahmed.el-marjou@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-118660"><name><surname>Vincent-Salomon</surname><given-names>Anne</given-names></name><email>anne.salomon@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-109252"><name><surname>Camonis</surname><given-names>Jacques</given-names></name><email>jacquescamonis@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-87543"><name><surname>Coppey</surname><given-names>Mathieu</given-names></name><email>mathieu.coppey@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-87541"><name><surname>Parrini</surname><given-names>Maria Carla</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7082-9792</contrib-id><email>maria-carla.parrini@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institut Curie, Centre de Recherche</institution><institution>Paris Sciences et Lettres Research University</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution>ART Group, Inserm U830</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Pathology</institution><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff4"><label>4</label><institution>LOCCO Group, UMR168</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Department of Biostatistics</institution><institution>Institut Curie</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff><aff id="aff6"><label>6</label><institution>Protein Expression and Purification Core Facility</institution><addr-line><named-content content-type="city">Paris</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Musacchio</surname><given-names>Andrea</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute of Molecular Physiology</institution><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Musacchio</surname><given-names>Andrea</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute of Molecular Physiology</institution><country>Germany</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>15</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e40474</elocation-id><history><date date-type="received" iso-8601-date="2018-07-31"><day>31</day><month>07</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2018-10-14"><day>14</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Zago et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Zago et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-40474-v3.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.40474.001</object-id><p>The two Ral GTPases, RalA and RalB, have crucial roles downstream Ras oncoproteins in human cancers; in particular, RalB is involved in invasion and metastasis. However, therapies targeting Ral signalling are not available yet. By a novel optogenetic approach, we found that light-controlled activation of Ral at plasma-membrane promotes the recruitment of the Wave Regulatory Complex (WRC) via its effector exocyst, with consequent induction of protrusions and invasion. We show that active Ras signals to RalB via two RalGEFs (Guanine nucleotide Exchange Factors), RGL1 and RGL2, to foster invasiveness; RalB contribution appears to be more important than that of MAPK and PI3K pathways. Moreover, on the clinical side, we uncovered a potential role of RalB in human breast cancers by determining that RalB expression at protein level increases in a manner consistent with progression toward metastasis. This work highlights the Ras-RGL1/2-RalB-exocyst-WRC axis as appealing target for novel anticancer strategies.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.40474.002</object-id><title>eLife digest</title><p>Cancers develop when cells in the body divide rapidly in an uncontroled manner. It is generally possible to cure cancers that remain contained within a small area. However, if the tumor cells start to move, the cancer may spread in the body and become life threatening. Currently, most of the anti-cancer treatments act to reduce the multiplication of these cells, but not their ability to migrate.</p><p>A signal protein called Ras stimulates human cells to grow and move around. In healthy cells, the activity of Ras is tightly controled to ensure cells only divide and migrate at particular times, but in roughly 30% of all human cancers, Ras is abnormally active. Ras switches on another protein, named RalB, which is also involved in inappropriate cell migration. Yet, it is not clear how RalB is capable to help Ras trigger the migration of cells.</p><p>Zago et al. used an approach called optogenetics to specifically activate the RalB protein in human cells using a laser that produces blue light. When activated, the light-controlled RalB started abnormal cell migration; this was used to dissect which molecules and mechanisms were involved in the process.</p><p>Taken together, the experiments showed that, first, Ras ‘turns on’ RalB by changing the location of two proteins that control RalB. Then, the activated RalB regulates the exocyst, a group of proteins that travel within the cell. In turn, the exocyst recruits another group of proteins, named the Wave complex, which is part of the molecular motor required for cells to migrate.</p><p>Zago et al. also found that, in patients, the RalB protein was present at abnormally high levels in samples of breast cancer cells that had migrated to another part of the body. Overall, these findings indicate that the role of RalB protein in human cancers is larger than previously thought, and they highlight a new pathway that could be a target for new anti-cancer drugs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Invasion</kwd><kwd>Ral</kwd><kwd>breast cancer</kwd><kwd>Exocyst</kwd><kwd>Wave</kwd><kwd>optogenetics</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004097</institution-id><institution>Fondation ARC pour la Recherche sur le Cancer</institution></institution-wrap></funding-source><award-id>PJA 20151203371</award-id><principal-award-recipient><name><surname>Parrini</surname><given-names>Maria Carla</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001677</institution-id><institution>Institut National de la Santé et de la Recherche Médicale</institution></institution-wrap></funding-source><award-id>PC201530</award-id><principal-award-recipient><name><surname>Coppey</surname><given-names>Mathieu</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001665</institution-id><institution>Agence Nationale de la Recherche</institution></institution-wrap></funding-source><award-id>ANR-10-IDEX-0001-02 PSL</award-id><principal-award-recipient><name><surname>Coppey</surname><given-names>Mathieu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>By moving from correlations to causality in cancer signal transduction using optogenetics, the sufficiency of RalB activation to trigger invasion and the underlying molecular mechanisms were established.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>One of the most frequent oncogenic events in human cancers is the activation by constitutive mutations of Ras GTPases: K-Ras, H-Ras, N-Ras. Roughly 30% of all human tumors carry Ras genetic alterations; the Ras mutation frequency is particularly high for pancreas (91%), lung (33%) and colon (51%) cancers (cbioportal) (<xref ref-type="bibr" rid="bib11">Gao et al., 2013</xref>; <xref ref-type="bibr" rid="bib44">Simanshu et al., 2017</xref>). Up-to-date no effective targeted therapies can be offered to patients with tumors carrying Ras mutations. Since Ras proteins are still considered undruggable (<xref ref-type="bibr" rid="bib8">Cox et al., 2014</xref>), the focus for anti-Ras drug discovery moved downstream. Ras activates three major downstream pathways: the MAP kinases, the PI3 kinases and the Ral GTPases. Despite the considerable translational research efforts on the downstream kinases, the results are very deceiving. For example, MAPK pathway inhibition with MEK inhibitor therapy turned out to be largely ineffective (<xref ref-type="bibr" rid="bib18">Jänne et al., 2013</xref>).</p><p>On the other hand, the targeting of Ral GTPases has been a much less exploited strategy (<xref ref-type="bibr" rid="bib53">Yan et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Yan and Theodorescu, 2018</xref>). The two human Ral proteins (RalA and RalB) are activated by six RalGEFs (Guanine Nucleotide Exchange Factors) (<xref ref-type="bibr" rid="bib30">Neel et al., 2011</xref>). Among the six, four RalGEFs (RalGDS, Rgl1, Rgl2, Rgl3) have a Ras-association (RA) domain and are direct effectors of Ras. Activated GTP-bound Ras recruits these RalGEFs at the plasma-membrane triggering the activation of Ral by GDP to GTP exchange. The two remaining RALGEFs (RalGPS1 and RalGPS2) do not bind Ras; their specific activators are still unknown, but they do contain a pleckstrin homology (PH) domain (<xref ref-type="bibr" rid="bib37">Rebhun et al., 2000</xref>), responsible for membrane targeting, and a proline-rich motif which binds to SH3-containing signaling proteins (<xref ref-type="bibr" rid="bib6">Ceriani et al., 2007</xref>).</p><p>Even though, in some cellular contexts, RalA and RalB seem to have overlapping effects, several evidences pointed out a distinct role for RalB in supporting the invasiveness of transformed cells. In the case of migration of the UMUC3 human bladder cancer cell line (K-Ras mutated), RalA seems to even antagonize the pro-migratory function of RalB (<xref ref-type="bibr" rid="bib33">Oxford et al., 2005</xref>). The requirement of RalB for invasion in vitro (by Transwell Invasion assay) was shown by shRNA knock-down approach in seven out of nine K-Ras mutated human pancreatic cancer cell lines (<xref ref-type="bibr" rid="bib24">Lim et al., 2006</xref>). Consistently, another study showed that RalB, but not RalA, plays a role in invadopodia formation in human pancreatic cancer cell lines (<xref ref-type="bibr" rid="bib31">Neel et al., 2012</xref>). RalB, but not RalA, is required for the contractility-driven invasion of lung cancer cells (A549, K-Ras mutated) (<xref ref-type="bibr" rid="bib3">Biondini et al., 2015</xref>). Moreover, in vivo metastasis assays in mice (tail vein injection) (<xref ref-type="bibr" rid="bib50">Ward et al., 2001</xref>; <xref ref-type="bibr" rid="bib24">Lim et al., 2006</xref>) and in hamsters (subcutaneous injection) (<xref ref-type="bibr" rid="bib41">Rybko et al., 2011</xref>) supported a function of RalB pathway in the formation of tumor metastasis, both in Ras-mutated and Rous sarcoma virus-transformed cells. Besides the cancer context, we previously found that RalB, but not RalA, controls the mesenchymal migration of normal cells (NRK, HEK-HT, wild-type for Ras) by mobilizing its effector exocyst (<xref ref-type="bibr" rid="bib40">Rossé et al., 2006</xref>; <xref ref-type="bibr" rid="bib34">Parrini et al., 2011</xref>; <xref ref-type="bibr" rid="bib4">Biondini et al., 2016</xref>), which is an octameric protein complex involved in the tethering of secretory vesicles to the plasma membrane prior to SNARE-mediated fusion (<xref ref-type="bibr" rid="bib52">Wu and Guo, 2015</xref>).</p><p>All these works allowed to recognize the relevance of RalB pathway for motility, invasion and metastasis, but the underlying molecular mechanisms remain elusive (<xref ref-type="bibr" rid="bib31">Neel et al., 2012</xref>). We reasoned that the emerging optogenetics technology (<xref ref-type="bibr" rid="bib48">Toettcher et al., 2013</xref>; <xref ref-type="bibr" rid="bib47">Tischer and Weiner, 2014</xref>) might help to overcome this limitation, because of its capacity to dissect the cause-effect relationships linking the activity of a specific protein of interest and the consequent cell behaviors, in time and space. To date, various light-gated protein-interaction modules have been introduced to perturb intracellular protein activities. The one we exploited is based on the interaction between two proteins from <italic>Arabidopsis Thaliana:</italic> CIB1 and cryptochrome 2 (CRY2) (<xref ref-type="bibr" rid="bib21">Kennedy et al., 2010</xref>). Blue-light illumination induces the heterodimerization of CRY2 with the N-terminus of CIB1 (CIBN). This reaction is reversible and rapid, with response times in the order of seconds (few seconds for dimerization and ~5 min for dissociation after cessation of blue illumination), and does not require exogenous cofactors. In this work, we applied the CRY2-CIBN light dimerization system to selectively activate Ral cascade and to study the primordial phenotypic effect of this activation.</p><p>By using this novel optogenetics approach, we precisely established the molecular mechanism underlying the capacity of RalB to drive invasion. This mechanism involves the exocyst-dependent recruitment at the leading edge of the Wave Regulatory Complex (WRC), a five-subunit protein complex involved in the formation of the actin cytoskeleton through interaction with the Arp2/3 complex (<xref ref-type="bibr" rid="bib1">Alekhina et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2014</xref>), but unexpectedly independently of the small GTPase Rac1, a well-established WRC activator and master regulator of protrusions (<xref ref-type="bibr" rid="bib38">Ridley et al., 1992</xref>; <xref ref-type="bibr" rid="bib39">Ridley, 2006</xref>). We also found that RalB pathway contribution might be much more relevant than MAPK and PI3K contributions to drive Ras-dependent invasion, as ascertained by using a genetically controlled cell model: the isogenic pair HEK-HT and HEK-HT-H-RasV12 (<xref ref-type="bibr" rid="bib14">Hahn et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">O'Hayer and Counter, 2006</xref>). Light-induced Ral activation was instructive in promoting cell invasion of the non-transformed HEK-HT cells. Finally, we analyzed Ral proteins’ expression in a cohort of breast cancer samples, pointing out for the first time a potential role of RalB in the invasiveness and metastatic spread of human breast cancers.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Optogenetic control for selective activation of ral proteins</title><p>We exploited the CRY2/CIBN light-gated dimerization system (<xref ref-type="bibr" rid="bib21">Kennedy et al., 2010</xref>) to induce activation of endogenous RalA and RalB proteins with a spatial and temporal control. We chose to activate Ral at the plasma-membrane because Ral oncogenic signaling emanates at least in part from the plasma-membrane (<xref ref-type="bibr" rid="bib50">Ward et al., 2001</xref>; <xref ref-type="bibr" rid="bib15">Hamad et al., 2002</xref>; <xref ref-type="bibr" rid="bib23">Lim et al., 2005</xref>). To do so, the GFP-fused CIBN protein was constitutively targeted to the plasma membrane via a K-Ras CAAX motif. The minimal GEF domain of RGL2 (1–518 aa), which is catalytically active on both RalA and RalB (<xref ref-type="bibr" rid="bib10">Ferro et al., 2008</xref>), was fused to CRY2-mCherry (RalGEF-CRY2-mCherry). We stably expressed these two constructs in HEK-HT cells, which are immortalized but not transformed (<xref ref-type="bibr" rid="bib14">Hahn et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">O'Hayer and Counter, 2006</xref>), to generate the ‘OptoRal’ cell line (CIBN-CAAX/RalGEF-CRY2). As control, we generated the ‘OptoControl’ cell line which expresses CRY2-mCherry only, without the RalGEF domain (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Upon blue light illumination (100 ms pulses every 15 s), RalGEF-CRY2-mCherry reversibly translocated to the plasma membrane following its binding to GFP-CIBN-CAAX (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), as shown by TIRF microscopy (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="video" rid="video1">Video 1</xref>). Fluorescence quantifications inside the illuminated area showed that RalGEF-CRY2 recruitment starts in less than 15 s, as expected (<xref ref-type="bibr" rid="bib49">Valon et al., 2015</xref>), reaching a threefold increase in few minutes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.003</object-id><label>Figure 1.</label><caption><title>Optogenetic control of Ral activation.</title><p>(<bold>A</bold>) The OptoRal strategy. Upon blue light stimulation the RalGEF domain of RGL2, fused to CRY2, is recruited to the plasma membrane following the interaction between CRY2 and CIBN, which is targeted to the plasma membrane by a CAAX prenylation motif. mCherry and GFP fluorescent proteins were used to monitor expression and localization of RalGEF-CRY2 and CIBN, respectively. After recruitment, the RalGEF induces activation of endogenous Ral. (<bold>B</bold>) Representative RalGEF-CRY2-mCherry recruitment. The fluorescent RalGEF-CRY2-mCherry fusion protein was imaged by TIRF microscopy before illumination (dark) and 8 min after blue light stimulation inside the blue square area (100 ms pulses every 15 s). Scale bar, 10 μm. See <xref ref-type="video" rid="video1">Video 1</xref> for the entire sequence. (<bold>C</bold>) Quantification of RalGEF-CRY2-mCherry recruitment. Average time course of the fold increase of mCherry fluorescence, that is RalGEF recruitment, inside the illuminated square area, is calculated from n = 20 cells from three independent experiments. Lines represent the mean, shaded regions represent the standard deviation (SD). (<bold>D</bold>) Representative Ral activation. The fluorescent RalGEF-CRY2-mCherry and Sec5GBD-iRFP (reporter of Ral activity) fusion proteins were simultaneously imaged by TIRF microscopy. Scale bar, 10 μm. See <xref ref-type="video" rid="video2">Video 2</xref> for the entire sequence. (<bold>E</bold>) Light activates RalB, but not Rac1 or Cdc42. OptoRal cells were transiently transfected to express: Sec5GBD-iRFP (reporter of Ral activity) with GFP-RalB (red line), Pak1GBD-iRFP (reporter of Rac1/Cdc42 activity) with GFP-Rac1 (blue line) or Pak1GBD-iRFP with GFP-Cdc42, respectively (light blue line). Average time course of the fold increase of iRFP fluorescence, that is Ral or Rac1/Cdc42 activities, inside the illuminated square area, is calculated from n = 6 cells per condition from three independent experiments. Lines represent the mean, shaded regions represent the standard deviation (SD).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig1-v3"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Optogenetic pair expression.</title><p>(<bold>A</bold>) Representative images of RalGEF-CRY-mCherry and CIBN-GFP-CAAX signals by epifluorescence microscopy before blue light stimulation in OptoRal cells. (<bold>B</bold>) Representative images of CRY-mCherry and CIBN-GFP-CAAX signals by epifluorescence microscopy before blue light stimulation in OptoControl cells. (<bold>C</bold>) Representative western blots for Cherry and GFP from cell lysates of OptoControl and OptoRal cells. GAPDH is used as loading control. The 110 kDa band in the Cherry western blot is non-specific.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig1-figsupp1-v3"/></fig></fig-group><media id="video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.005</object-id><label>Video 1.</label><caption><title>Blue light induces local recruitment at plasma membrane of RalGEF-CRY2-mCherry in OptoRal cells.</title><p>OptoRal cells were imaged by TIRF microscopy (Cherry channel). Cells were illuminated inside the blue rectangle starting at time t = 2.15 min. Scale bar is 10 μm. Time length: 8.5 min. Images were acquired every 15 s and the video is shown at 7 frame/s.</p></caption></media><p>In order to assess whether the recruitment of RalGEF-CRY2 was converted in an efficient Ral activation, we used a Ral activity reporter: the iRFP-tagged Ral GTPase Binding Domain of Sec5 (Sec5GBD), which specifically interacts with both RalA and RalB in their GTP loaded forms (<xref ref-type="bibr" rid="bib46">Takaya et al., 2004</xref>). Since the Sec5GBD-iRFP reporter proteins were in large excess with respect to the endogenous Ral proteins, we overexpressed GFP-RalB in OptoRal cells in order to increase the RalB:Sec5GBD stoichiometric ratio and to achieve the recruitment of a major, detectable fraction of Sec5GBD molecules. Upon blue light illumination, Sec5GBD-iRFP fluorescence at plasma membrane increased 1.4 fold (<xref ref-type="fig" rid="fig1">Figure 1D,E</xref> and <xref ref-type="video" rid="video2">Video 2</xref>), indicating an efficient activation of Ral proteins, presumably a combination of exogenous GFP-RalB, and endogenous RalA and RalB. The light-induced RalB activation was confirmed by pull-down assay (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and by a FRET-based RalB activity biosensor (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><media id="video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video2.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.006</object-id><label>Video 2.</label><caption><title>Blue light induces local Ral activation in OptoRal cells.</title><p>OptoRal cells expressing RalB-GFP and Sec5GBD-iRFP were imaged by TIRF microscopy. On the left, the recruitment of RalGEF is followed in the mCherry channel. On the right, the recruitment of Sec5GBD (reporter for Ral activity) is followed in the iRFP channel. Cells were illuminated inside the blue rectangle starting at time t = 2 min. Scale bar is 10 μm. Time length: 32.25 min. Images were acquired every 15 s and the video is shown at 7 frame/s.</p></caption></media><p>The activation was selective for Ral without cross activation of Rac1 or Cdc42, as shown by over-expressing GFP-Rac1 or GFP-Cdc42 together with a Rac1/Cdc42 activity reporter: the iRFP-tagged GTPase Binding Domain of Pak1 (Pak1GBD) (<xref ref-type="bibr" rid="bib49">Valon et al., 2015</xref>), which specifically interacts with Rac1-GTP and Cdc42-GTP (<xref ref-type="bibr" rid="bib43">Sells et al., 1997</xref>; <xref ref-type="bibr" rid="bib16">Huang et al., 2013</xref>). Upon blue light illumination, Pak1GBD-iRFP fluorescence at plasma membrane did not increase, on the contrary slightly decreased (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), indicating the absence of Rac1 or Cdc42 activation upon recruitment of RalGEF at the plasma membrane.</p><p>In conclusion, we developed an efficient and selective optogenetic OptoRal system to specifically trigger local activation of Ral proteins. Since the optogenetic perturbations act in a timescale (tens of second) much faster than the ones of endogenous feedbacks (minutes) (<xref ref-type="bibr" rid="bib49">Valon et al., 2015</xref>), this new approach allowed us to investigate the direct consequences of Ral activation, at both phenotypic and molecular levels.</p></sec><sec id="s2-2"><title>Local Ral activation triggers protrusions, independently of Rac1</title><p>A conspicuous phenotypic consequence of local Ral activation was an increase in cell edge dynamics, leading to protrusion formation (<xref ref-type="video" rid="video3">Video 3</xref>). By using an automated method (<xref ref-type="bibr" rid="bib35">Paul-Gilloteaux et al., 2018</xref>), we tracked over time the cell contour inside the illuminated area and we generated edge velocity maps (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The velocity maps of OptoRal cells showed an evident stimulation of cell edge dynamics after light stimulation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This stimulation corresponded, for the majority of the sampled space and time points, to an increase of positive velocity (i.e. protrusions) and not of negative velocities (i.e. retractions). In contrast, no changes of cell edge dynamics were observed upon light stimulation of OptoControl cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="video" rid="video4">Video 4</xref>), excluding non-specific effects due to illumination or to CRY2 recruitment. Moreover, the alternations of dark and light periods revealed that the velocity dynamics were reversible and exquisitely controllable by the illumination in OptoRal cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>) but not in the OptoControl cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>).</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.007</object-id><label>Figure 2.</label><caption><title>Local Ral activation induces protrusiveness.</title><p>(<bold>A</bold>) Cell edge dynamics inside the illuminated area were measured using an automated method. (<bold>B</bold>) Edge dynamics velocity map of a representative OptoRal cell before and after illumination (dotted blue line). See <xref ref-type="video" rid="video3">Video 3</xref> for the entire sequence. The color-coded map shows the velocity measurements for each sampled edge window (space, horizontal axis) and for each time point (time, vertical axis). Positive velocities (i.e. protrusion) are represented as warm color, negative velocities (i.e. retraction) as cold colors. As example of velocity profile over time, the velocity measurements are shown for a selected point in space (window 71) in the lower panel; the stimulation of edge velocity is visible immediately after light illumination. As examples of velocity profiles over the space dimension, the velocity measurements are shown in the right panels using the color-code along the cell edge for two selected time points, 1.4 min and 6.5 min, dark and light conditions, respectively. (<bold>C</bold>) Edge dynamics velocity map of a representative OptoControl cell before and after illumination. See <xref ref-type="video" rid="video4">Video 4</xref> for the entire sequence. The velocity profiles over time (window 77, lower panel) or over space (1.3 min and 5 min, right panels) show that illumination did not induce any change of edge velocity. (<bold>D</bold>) Quantification of edge velocities before and after illumination. Positive velocities (i.e. protrusion) and negative velocities (i.e. retraction) are analysed separately. Each white dot represents the mean of all velocity measurements (all time and space points) before illumination. Each blue dot represents the mean of all velocity measurements (all time and space points) after illumination. Measurements from a same cell are connected by lines. Illumination stimulates positive edge velocities in OptoRal cells (left) but not in OptoControl cells (centre). Inhibition of Rac with NSC23766 (100 µM, treatment started 1 hr before experiment) did not impair stimulation by light of positive edge velocities in OptoRal cells (right). Bars represent mean of n = 18 cells per condition ±SEM from three independent experiments. *** indicates p&lt;0.001, ** indicates p&lt;0.01 and ns indicates not-significant, using Wilcoxon signed-rank test for paired measurements (same cell pre- and post-illumination). There was no significant difference in the delta velocities pre- and post-illumination when comparing presence and absence of the NSC23766 inhibitor (using Student t-test, not shown). There was no significant difference in the pre-illumination edge velocities when comparing OptoRal and OptoControl cells (using Student t-test, not shown). (<bold>E</bold>) RalB depletion, but not RalA depletion, impairs stimulation of positive edge velocities in OptoRal cells. OptoRal cells were transfected with the indicated siRNAs and analysed as in panel D. n = 10–11 cells per condition.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig2-v3"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.008</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Additional evidences that light stimulates RalB activity in OptoRal cells.</title><p>(<bold>A</bold>) Pull-down assay of RalB-GTP in dark and after blue light stimulation (5 min), in OptoControl and OptoRal cells, using Sec5GBD beads. The quantifications express the RalB-GTP/total RalB ratios, normalized for OptoControl dark condition. Cells were starved overnight in DMEM supplemented 0.2% FBS before the assay. For dark conditions, cells were kept in a dark box to avoid daylight exposure and lysed in a dark room. For light conditions, cells were exposed to 488 nm excitation illumination under an epifluorescence microscope for 5 min prior lysis. (<bold>B</bold>) Visualization of RalB activity by FRET. OptoRal cells, expressing a RalB FRET-based biosensor, were imaged by FRET miscoscopy; in such setting, since the CFP stimulation results in optogenetics activation, the first time point is taken as dark condition. The graph shows the average ±SD whole cell FRET measurements from n = 3 cells. Scale bar, 10 µm.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig2-figsupp1-v3"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.009</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Reversibility and repeatability of edge velocity stimulation by light. Validation of Rac1 inhibition and of RalA and RalB depletion. </title><p>(<bold>A</bold>) Edge dynamics velocity maps of OptoRal cells upon alternation of dark and light periods. Pulsed light stimulation was alternated with periods of dark as following: 3 min dark, 10 min light, 20 min dark, and 10 min light. On the left, the velocity measurements over the time are shown for a selected space point (window 52). The stimulation of edge velocity repeatedly occurs immediately after light illumination. Upon switch off to dark, the reversion to base-line edge velocity occurs within 10 min. (<bold>B</bold>) Edge dynamics velocity maps of OptoControl cells upon alternation of dark and light periods. No matter light or dark, only small stochastic fluctuations of edge velocity are observed. (<bold>C</bold>) Validation of Rac1 inhibition by NSC23766 treatment. OptoRal cells were incubated 1 hr with 100 µM NSC23766 prior to cell lysis. Cell lysates were subjected to Rac1-GTP pull-down assay using Pak1GBD beads. The quantifications express the Rac1-GTP/total Rac1 ratios, normalized for control condition without treatment. (<bold>D</bold>) Validation of Ral depletions for cell edge dynamics in OptoRal cells. Representative western blots from cell lysates prepared 72 hr after transfection with the indicated siRNA. GAPDH was used as loading control. Quantifications of Ral depletion efficiencies, calculated as Ral/GAPDH and normalized for siControl, are shown below the WBs.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig2-figsupp2-v3"/></fig></fig-group><media id="video3" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video3.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.010</object-id><label>Video 3.</label><caption><title>Local activation of Ral induces protrusions.</title><p>On the left, optogenetic recruitment of of RalGEF(Cherry channel) in OptoRal cells imaged by TIRF microscopy. On the right, threshold-based binary mask of the cells used to calculate the edge velocity. Cells were illuminated inside the blue rectangle starting at time t = 3.10 min. Scale bar is 10 μm. Time length: 6.83 min. Images were acquired every 10 s and the video is shown at 7 frame/s.</p></caption></media><media id="video4" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video4.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.011</object-id><label>Video 4.</label><caption><title>Light stimulation of OptoControl cells does not induce protrusions.</title><p>Same conditions as <xref ref-type="video" rid="video3">Video 3</xref>.</p></caption></media><p>The quantifications of edge velocities from several OptoRal cells before and after illumination showed a highly significant increase of membrane protrusion events, but not of retraction events; this increase was not found in OptoControl cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). To address a possible role of Rac in this phenotype we treated the OptoRal cells with the RacGEF inhibitor NSC23766. Treatment with NSC23766 (100 µM, 1 hr) substantially reduced (~60%) Rac1-GTP level (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>), but it did not impair a fully efficient protrusion induction by illumination in OptoRal cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), suggesting that Rac1 have a marginal role in stimulation of edge velocities when Ral proteins are activated. Importantly, blue illumination of OptoRal cells does not activate at all Rac1, as shown by the Pak1GBD fluorescent reporter (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). These results together support the conclusion that Ral triggers protrusion independently of Rac1.</p><p>Our OptoRal system is designed to activate both endogenous RalA and RalB. However, RalB-depleted cells, but not RalA depleted cells, were impaired in protrusions formation, proving that light-controlled stimulation of cell protrusions is essentially due to activation of endogenous RalB, rather than RalA (<xref ref-type="fig" rid="fig2">Figure 2E</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref> for depletion validation), consistently with the well-established specific role of RalB in the regulation of motility and invasion (see Introduction).</p></sec><sec id="s2-3"><title>Upon Ral activation the WRC complex is recruited at the cell front via its association to the exocyst complex</title><p>Next, we addressed the question of the molecular mechanisms underlying the capacity of RalB to trigger protrusions independently of Rac1. A previous work in our lab (<xref ref-type="bibr" rid="bib4">Biondini et al., 2016</xref>) established the existence of an interaction between the Wave Regulatory Complex (WRC), a crucial regulator of actin polymerization and protrusion formations (<xref ref-type="bibr" rid="bib1">Alekhina et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2014</xref>), and the exocyst complex (<xref ref-type="bibr" rid="bib52">Wu and Guo, 2015</xref>), a major direct effector of Ral, but the functional consequences of this interaction are still unclear. We reasoned that Ral activation might promote the trafficking and recruitment of the exocyst/WRC complex assembly at the leading edge (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). To test this hypothesis, we generated OptoRal and OptoControl cell lines stably expressing the iRFP-fused Abi1 subunit of WRC complex. The correct incorporation of iRFP-Abi1 into the WRC complex was verified by size exclusion chromatography: the exogenous iRFP-Abi1, as well as the endogenous Abi1, co-eluted with the Cyfip subunit in fractions of approximately 400 kDa corresponding to the size of the whole WRC complex (<xref ref-type="bibr" rid="bib12">Gautreau et al., 2004</xref>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.012</object-id><label>Figure 3.</label><caption><title>Local Ral activation induces WRC complex recruitment at the edge and ventral plasmamembrane via the exocyst.</title><p>(<bold>A</bold>) Working model. Upon Ral activation, exocyst is assembled and recruited at the plasma membrane, functioning as transporter for the WRC complex. The model was tested by monitoring the recruitment of WRC by TIRF microscopy using a fluorescent-tagged Abi1 subunit of WRC (iRFP-Abi1). (<bold>B</bold>) Representative iRFP-Abi1 recruitment (reporter of WRC localization) in OptoRal cells. The fluorescent RalGEF-CRY2-mCherry and iRFP-Abi1 fusion proteins were simultaneously imaged with TIRF microscopy before and 7 min after blue light stimulation. Scale bar, 10 μm. See <xref ref-type="video" rid="video5">Video 5</xref> for the entire sequence. The variations of iRFP fluorescence were measured both at the ventral compartment (green circle) and at the leading edge (orange lines) of the cells. (<bold>C</bold>) Representative absence of light-dependent iRFP-Abi1 recruitment in OptoControl cells. Scale bar, 10 μm. See <xref ref-type="video" rid="video6">Video 6</xref>. There is an increase of mCherry but not of iRFP fluorescence after illumination. (<bold>D</bold>) Color-coded maps show the WRC edge recruitment in the OptoRal cell of panel B and in the OptoControl cell of panel C, calculated across a band with a width of 1.12 µm, before and after illumination, for each sampled edge window (space, horizontal axis) and for each time point (time, vertical axis). In the OptoRal cell (left), changes to warmer colors after illumination indicate increased WRC recruitment. In the OptoControl cell (right), there are no changes of WRC edge recruitment after illumination. (<bold>E</bold>) Quantification of ventral iRFP-Abi1 recruitment: comparison of OptoRal iRFP-Abi1 wild-type (WT), OptoControl iRFP-Abi1 wild-type (WT), and OptoRal iRFP-Abi1Q56A cells. Average time course of the fold increase of iRFP fluorescence, that is WRC recruitment, is calculated from n = 15 cells per condition from four independent experiments. Lines represent the mean, shaded regions represent the standard deviation (SD). Statistical comparison of the three curves was done using Student t-test at 2, 4, 6, 8, 10 min time points: *p&lt;0.05, **p&lt;0.01, ***, p&lt;0.001, ns not-significant. Only the OptoRal iRFP-Abi1 wild-type curve diverges after light stimulation (at 6 min). (<bold>F</bold>) Quantification of edge velocities before and after illumination: comparison Abi1 wild-type (WT) versus Abi1Q56A in OptoRal cells. See legend <xref ref-type="fig" rid="fig2">Figure 2D</xref> for details. Illumination stimulates positive edge velocities in OptoRal cells expressing Abi1 WT (left) but not in OptoRal cells expressing Abi1Q56A (right). Bars represent mean of n = 15 cells per condition ±SEM from three independent experiments. *** indicates p&lt;0.001 and ns indicates not-significant, using Wilcoxon signed-rank test for paired measurements (same cell pre- and post-illumination).</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig3-v3"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.013</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Size exclusion chromatography shows incorporation of exogenous iRFP-Abi1 (both wild-type and Q56A) into the whole WRC complex.</title><p>Total lysates from OptoRal cells expressing iRFP-Abi1 WT (<bold>A</bold>), from OptoControl cells expressing iRFP-Abi1 WT (<bold>B</bold>), or from OptoRal cells expressing iRFP-Abi1Q56A (<bold>C</bold>) were subjected to analytical size exclusion chromatography on a Superose 610/300 GL column. Input and fractions were analyzed by western blot using anti-Abi and anti-Cyfip antibodies. Exogenous iRFP-Abi fusion proteins co-eluted with endogenous Cyfip in the high molecular weight fractions, confirming that the fusion protein is incorporated in the WRC complex.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig3-figsupp1-v3"/></fig></fig-group><p>We locally activated Ral at cell periphery and followed iRFP-Abi1 recruitment. For convenience of imaging, we limited the inter-cellular morphology variability by subjecting the OptoRal cells to wound healing, leading to the formation of large front lamellipodia where Ral was activated by light. TIRF images showed that Ral activation induced an immediate increase of iRFP-Abi1 signal at the plasma membrane, both at the leading edge and at the ventral side (<xref ref-type="fig" rid="fig3">Figure 3B</xref> snapshots and <xref ref-type="video" rid="video5">Video 5</xref>). In contrast, OptoControl cells did not show any light-dependent iRFP-Abi1 recruitment (<xref ref-type="fig" rid="fig3">Figure 3C</xref> snapshots and <xref ref-type="video" rid="video6">Video 6</xref>). WRC edge recruitment was quantified by using an automated method that measures the maximum fluorescent intensity at the edge (width of 1.12 µm) (<xref ref-type="bibr" rid="bib35">Paul-Gilloteaux et al., 2018</xref>): the resulting heat maps show a dynamic edge fluorescence appearing upon illumination in OptoRal cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, left) but not in OptoControl cells (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, right). We could not apply this method of quantification at the edge on all the imaged cells, because the leading edge was often lifted above the ventral plan captured by TIRF and because the cycling dynamics (protrusion-retraction alternation and on-off Abi1 recruitment) were very fast. Instead, fluorescence quantifications from several OptoRal and OptoControl cells could be easily done at ventral location inside the illuminated area: iRFP-Abi1 was recruited in OptoRal cells but not in OptoControl cells, with a robust statistical significance (<xref ref-type="fig" rid="fig3">Figure 3E</xref>).</p><media id="video5" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video5.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.014</object-id><label>Video 5.</label><caption><title>Local activation of Ral induces WRC recruitment at plasma membrane.</title><p>OptoRal cells expressing iRFP-Abi WT were imaged by TIRF microscopy. On the left, the recruitment of RalGEF is followed in the mCherry channel. On the right, the recruitment of Abi1 (a subunit of WRC complex) is followed in the iRFP channel. Cells were illuminated inside the blue rectangle starting at t = 5 min. Scale bar is 10 μm. Time length: 10.17 min. Images were acquired every 10 s and the videos are shown at 7 frame/s.</p></caption></media><media id="video6" mime-subtype="mp4" mimetype="video" xlink:href="elife-40474-video6.mp4"><object-id pub-id-type="doi">10.7554/eLife.40474.015</object-id><label>Video 6.</label><caption><title>Light stimulation of OptoControl cells does not induce WRC recruitment at plasma membrane.</title><p>Same conditions as <xref ref-type="video" rid="video5">Video 5</xref>.</p></caption></media><p>To demonstrate that WRC translocation is a direct consequence of its association with the exocyst, we exploited a previously characterized loss-of-interaction Abi1 mutant, Abi1Q56A, which is specifically impaired in its binding to the Exo70 subunit of exocyst (<xref ref-type="bibr" rid="bib4">Biondini et al., 2016</xref>). We generated an OptoRal cell line expressing the iRFP-Abi1Q56A mutant and we verified its correct incorporation into WRC by size exclusion chromatography (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). The analysis of several cells showed that upon Ral activation the recruitment at the ventral plasma membrane of the AbiQ56A mutant was significantly and substantially reduced with respect to wild-type Abi1 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), indicating that the WRC/exocyst association is required for efficient translocation of WRC complex. Moreover, while illumination stimulated edge velocity of OptoRal cells expressing Abi1 wild-type, it was not effective in stimulating edge velocity of OptoRal cells expressing the Abi1Q56A mutant (<xref ref-type="fig" rid="fig3">Figure 3F</xref>), indicating that reduction of WRC recruitment correlated with a decrease in protrusion dynamics.</p></sec><sec id="s2-4"><title>Activation of Ral-exocyst-WRC axis promotes invasion of non-transformed cells</title><p>In order to functionally assess the impact on invasion of light-controlled Ral activation, we performed a Transwell invasion assay coupled with optogenetic illumination. For this purpose, we designed and built a customized 12-well array LED to deliver optical stimuli to the cells inside the Transwells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Blue light was administrated continuously from the bottom of the Transwell plate for the whole duration of the invasion assay (6 hr). Using this device, we compared the invasive capabilities of OptoControl and OptoRal cells, as well of OptoControl iRFP-Abi1 wild-type, OptoRal iRFP-Abi1 wild-type, and OptoRal iRFP-Abi1Q56A, in both dark and light stimulation conditions.</p><p>Illumination of OptoRal cells, but not of OptoControl cells, was sufficient to induce a substantial increase of invasive capabilities (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Similar results were obtained upon expression of the wild-type Abi1 subunit of WRC complex, whereas OptoRal cells expressing Abi1Q56A (the allele specifically impaired in its binding to exocyst [<xref ref-type="bibr" rid="bib4">Biondini et al., 2016</xref>]) failed to invade upon light stimulation (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These results strongly support the conclusion that activation of Ral drives cell invasion by recruiting WRC via the exocyst.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.016</object-id><label>Figure 4.</label><caption><title>Activation of Ral triggers invasion of non-transformed cells.</title><p>(<bold>A</bold>) Transwell invasion assay with OptoControl and OptoRal cells, in the dark or under light stimulation. Graph shows the mean ±SEM from three independent experiments. In the graph the results of one-way ANOVA tests are reported to compare pairs of conditions. (<bold>B</bold>) Transwell invasion assay with OptoControl iRFP-Abi1 wild-type, OptoRal iRFP-Abi1 wild-type, and OptoRal iRFP-Abi1Q56A cells, in the dark or under light stimulation. Graph shows the mean ±SEM from five independent experiments. In the graph the results of one-way ANOVA tests are reported to compare pairs of conditions. *p&lt;0.05, **p&lt;0.01, ***, p&lt;0.001, ns not-significant.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig4-v3"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.017</object-id><label>Figure 4—figure supplement 1.</label><caption><title>The custom-made illumination device for optogenetic activation on multi-well dishes.</title><p>(<bold>A</bold>) The device consists of an array of 12 blue LEDs mounted in a 3D-printed enclosure so that each LED illuminates one well only of a 12-well plate. Cells were illuminated from the bottom of the plate and the device was kept in a cell-culture incubator for the whole duration of the experiments. (<bold>B</bold>) Each LED is controlled independently through an Arduino Due micro-controller.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig4-figsupp1-v3"/></fig></fig-group></sec><sec id="s2-5"><title>Ras-driven cancer invasion requires activation of RalB via RGL1 and RGL2</title><p>To evaluate the contribution of Ral activation downstream oncogenic Ras in cell invasion, we took advantage of the fact that HEK-HT cells, non-transformed, develop a tumorigenic, invasive and metastatic phenotype in vivo upon expression of oncogenic H-RasV12 (<xref ref-type="bibr" rid="bib14">Hahn et al., 1999</xref>; <xref ref-type="bibr" rid="bib32">O'Hayer and Counter, 2006</xref>). We compared this isogenic pair, HEK-HT and HEK-HTRasV12, by using two different in vitro invasion assays: the widely used ‘Transwell Invasion assay’ (invasion through a thin matrigel layer) and the ‘Inverted Invasion assay’ with a more 3D setting (invasion through a thick collagen gel). In both assays, we found as expected that HEK-HT cells did not invade at all, while HEK-HT-RasV12 displayed a strong invasive capacity (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). Interestingly, the HEK-HT-RasV12 cells invaded as multi-cellular clusters in the 3D collagen gel (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, photos below).</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.018</object-id><label>Figure 5.</label><caption><title>Ras-driven invasion requires RalB, rather than MAPK and PI3K.</title><p>(<bold>A</bold>) Comparison of invasive capability of HEK-HT and HEK-HT-H-RasV12 cells through a thin matrigel layer using Transwell invasion assay (6 hr). Representative images of invading cells stained with DAPI are shown below the graph. Scale bar, 50 µm. Graph shows the mean ±SEM. Each dot represents one experiment. For statistics Student t-test was used. (<bold>B</bold>) Comparison of invasive capability of HEK-HT and HEK-HT-HRasV12 cells through a 3D bovine collagen gel (2.3 mg/ml) using Inverted invasion assay (4 days). Cells were live stained with CellTrace. Invasion was quantified as mean fluorescence of confocal fields acquired every 5 µm starting from below the porous membrane till 200 µm distance inside the gel. Graph shows the mean ±SD of measurements in duplicate from three experiments. Representative images are shown below the graph. Scale bar, 250 µm. Statistical comparison of the curves was done using Student t-test at every 25 µm. (<bold>C</bold>) RalB but not RalA is required for HEK-HTRasV12 invasion through a matrigel layer (Transwell invasion assay). Cells were transfected with the indicated siRNAs. For statistics one-way ANOVA test was used. (<bold>D</bold>) RalB is required for HEK-HTRasV12 invasion through a 3D collagen gel (Inverted invasion assay). Invasion was quantified as in panel B. (<bold>E</bold>) Comparison of invasive capability of HEK-HT-H-RasV12, HEK-HT-H-RasV12G37 and PIK90-treated HEK-HT-H-RasV12G37 cell lines using Transwell invasion assay. The combination of the additional G37 mutation and treatment with the PI3K inhibitor PIK90 (10 µM, treatment started 1 hr before Transwell invasion assay and maintained during the 6 hr invasion) impairs RasV12-dependent MAPK and PI3K hyperactivation, conserving only the activation of Ral pathway. For statistics one-way ANOVA test was used. (<bold>F</bold>) Comparison of invasive capability of HEK-HT-H-RasV12 cells treated with DMSO, with the MEK inhibitor Trametinib (10 nM), with the PI3K inhibitor PIK90 (2.5 μM), or with both Trametinib and PIK90. Treatments were started 1 hr before Transwell invasion assay and maintained during the 6 hr invasion. Cell lysates were prepared at 1 hr post-treatment. On the right, representative western blots for total Akt and phospho-Akt (Ser437), and for total Erk and phospho-Erk (Thr202/Tyr204), show the efficient pharmacological blockage of MAPK and PI3K pathways. Quantifications of Akt and Erk phosphorylation, calculated as p-Akt/total Akt or p-Erk/total Erk ratios, and normalized for HEK-HT-HRasV12 without drugs, are shown below the WBs. For statistics one-way ANOVA test was used. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig5-v3"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.019</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Representative western blots.</title><p>(<bold>A</bold>) Validation of Ral depletions for Transwell invasion assay. Representative western blots for RalA and RalB from cell lysates of HEK-HT-RasV12 cells, prepared 72 hr after transfection with the indicated siRNA. GAPDH is used as loading control. Quantifications of Ral depletion efficiencies, calculated as Ral/GAPDH ratio and normalized for siControl condition, are shown below the WBs. (<bold>B</bold>) Validation of Ral depletions for Inverted invasion assay. Representative western blots for RalA and RalB from cell lysates of HEK-HT-RasV12 cells, prepared 72 hr, 96 hr and 120 hr after transfection with the indicated siRNA. Adaptin is used as loading control. Quantifications of Ral depletion efficiencies, calculated as Ral/adaptin ratio and normalized for siControl condition at the same time point, are shown below the WBs. (<bold>C</bold>) Inhibition of MAPK pathway by G37 mutation. Representative western blot for total Erk and phospho-Erk (Thr202/Tyr204) from cell lysates of HEK-HT, HEK-HT-HRasV12, and HEK-HT-HRasV12G37 cells. Quantifications of Erk phosphorylation, calculated as p-Erk/total Erk ratio and normalized for HEK-HT-H-RasV12, are shown below the WBs. (<bold>D</bold>) Inhibition of PI3K pathway by PIK90. PIK90 (10 µM) treatment was started 1 hr before Transwell invasion assay and maintained during the 6 hr invasion. Cell lysates were prepared at 1 hr post-treatment. Representative western blot for total Akt and p-Akt (Ser437) from cell lysates of HEK-HT-HRasV12G37 cells, treated or not with PIK90 (10 µM). GAPDH is used as loading control. Quantifications of Akt phosphorylation, calculated as p-Akt/total Akt ratio and normalized for HEK-HT-H-RasV12G37 without PIK90, are shown below the WBs.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig5-figsupp1-v3"/></fig></fig-group><p>In HEK-HTRasV12 cells, the silencing of RalB impaired Transwell invasion of approximatively 60%, the silencing of RalA had not effect, and the silencing of both RalB and RalA reached up to 90% invasion inhibition (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref> for depletion efficiencies), indicating that Ras-dependent RalB activation substantially contributes to the invasive phenotype of Ras-mutated cells, and that RalA is dispensable, but it might partially compensate when RalB is absent. The specific role of RalB, with respect to RalA, for cell motility and invasion is in perfect agreement with several previous works (<xref ref-type="bibr" rid="bib33">Oxford et al., 2005</xref>; <xref ref-type="bibr" rid="bib40">Rossé et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Lim et al., 2006</xref>; <xref ref-type="bibr" rid="bib41">Rybko et al., 2011</xref>). The RalB requirement for in vitro invasion of HEK-HTRasV12 cells was confirmed using the Inverted Invasion assay with collagen (<xref ref-type="fig" rid="fig5">Figure 5D</xref>) (see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref> for depletion efficiency up to 5 days post-siRNA transfection).</p><p>The double mutant H-RasV12G37, which is completely impaired in stimulating MAP kinase activity but maintains Ral activation (<xref ref-type="bibr" rid="bib51">White et al., 1995</xref>; <xref ref-type="bibr" rid="bib2">Bettoun et al., 2016</xref>) (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), showed the same invasive capabilities by Transwell invasion assay as compared with H-RasV12 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, center), indicating that Ras-dependent MAPK hyper-activation is dispensable to drive efficient invasion, in this genetically controlled cell model. Since HEK-HT-RasV12G37 cells retained a residual Ras-dependent activation of PI3K pathway activation, as assessed by AKT phosphorylation (<xref ref-type="bibr" rid="bib23">Lim et al., 2005</xref>; <xref ref-type="bibr" rid="bib2">Bettoun et al., 2016</xref>), we used a PI3K inhibitor (PIK90), which targets all PI3K isoforms, to completely inhibit PI3K pathway (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). PIK90-treated HEK-HT-RasV12G37 cells are still capable to invade as efficiently as untreated HEK-HT-RasV12G37 and HEK-HT-RasV12 cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, right), indicating that also Ras-dependent PI3K hyper-activation is dispensable to drive efficient Transwell invasion.</p><p>These unexpected results were confirmed with HEK-HT-RasV12 cells by a purely pharmacological approach using the MEK inhibitor trametinib and the PI3K inhibitor PIK90, alone or in combination. Despite a nearly complete inhibition of Erk or Akt phosphorylation, trametinib-treated or PIK90-treated HEK-HT-RasV12 cells were still able to invade to the same extent as control vehicle-treated cells; only the combined MAPK and PI3K blockage displayed an inhibitory tendency, although not statistically significant (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p><p>Taken together these results showed that the Ras-RalGEF-RalB signaling axis is necessary to promote invasion in Ras-transformed cells, while MAPK and PI3K pathways appear to be dispensable, at least in our experimental context.</p><p>Next, we aimed at identifying the missing molecular link between Ras and RalB, that is the specific RalGEFs implicated in Ras-dependent cell invasion. We thus silenced each of the six RalGEFs by two independent siRNA in HEK-HT-RasV12 cells. The depletion of RGL1 and RGL2 substantially reduced invasion. RLGL3, RalGDS and RalGPS1 were clearly not required for invasion, while RalGPS2 silencing showed a potential inhibitory effect, even though statistically not significant (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). RGL1 and RGL2 have a Ras-association domain (RA). We therefore concluded that RGL1 and RGL2 are the molecular actors that promote invasion down-stream oncogenic Ras by activating RalB.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.020</object-id><label>Figure 6.</label><caption><title>Ras-driven invasion requires the two RalGEF RGL1 and RGL2.</title><p>(<bold>A</bold>) HEK-HTRasV12 cells require RGL1 and RGL2 for Transwell invasion (upper panel). Depletions of the six RalGEF were validated by RT-qPCR (lower panel). Graphs show the mean ±SEM. Each dot represents one experiment. For statistics one-way ANOVA was used. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant. (<bold>B–C</bold>) Localization of endogenous RGL2 and RalB is increased at the cell edges of HEK-HTRasV12 transformed cells as compared to HEK-HT. Representative epifluorescence images of the immunostaining of RGL2 and RalB are depicted. Scale bar, 10 µm. Graphs show the averaged percentage ±SEM of cell perimeter which is positive for RGL2 or RalB. n &gt; 40 cells from four independent experiments. For statistics Student t-test was used. *p&lt;0.05, **p&lt;0.01, ***, p&lt;0.001, ns indicates not-significant. (<bold>D</bold>) The Ras-RGL1/2-RalB-exocyst-WRC axis drives invasion. Active Ras-GTP binds and recruit the two RalGEFs RGL1 and RGL2, which activate RalB; RalB-GTP binds to the exocyst complex, promoting its assembly and recruitment to the leading edge; by its direct association with the WRC complex, exocyst drives WRC to the leading edge, where WRC stimulates actin polymerization via the Arp2/3 complex, consequently promoting protrusion formation, motility and invasion.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig6-v3"/></fig><p>By immunofluorescence staining, we found that endogenous RGL2 (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) and RalB (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) were more recruited at cell edges in HEK-HTRasV12 cells with respect to normal HEK-HT cells, consistent with the model in which plasma-membrane Ras-GTP binds and recruits RGL2, which in turn binds and activates its substrate RalB, promoting invasiveness via exocyst-mediated WRC recruitment (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Noteworthy, both RGL2 and RalB localize also at endomembranes, where local signaling might drive additional outputs.</p></sec><sec id="s2-6"><title>RalB protein expression increases in a manner consistent with disease progression in human breast cancers</title><p>While Ral proteins have been involved in several cancers frequently carrying Ras mutations, such as pancreas, lung, colon, bladder, melanoma (<xref ref-type="bibr" rid="bib54">Yan and Theodorescu, 2018</xref>), their roles have not been explored in breast cancers, in which the Ras mutation frequency is rather low (2.3%) (cbioportal) (<xref ref-type="bibr" rid="bib11">Gao et al., 2013</xref>). We investigated by immunohistocytochemistry (IHC) the protein levels of RalA and RalB in 502 invasive ductal carcinoma representative of the four main molecular subtypes (luminal A, luminal B, HER2+, triple-negative) (see <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref> for intensity scores). In invasive ductal carcinoma, RalB protein expression was slightly higher in luminal A and B than in HER2 +and triple-negative (TN) tumors (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>), while RalA protein expression was slightly lower in TN tumors as compared to the other subtypes (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). More interestingly, both RalB and RalA expression was higher in tumor cells than in normal juxtatumoral cells (<xref ref-type="fig" rid="fig7">Figure 7A,B</xref>). We also relatively compared the Ral staining at in situ and invasive compartments of invasive ductal carcinoma, and at lymph node metastasis. Strikingly, RalB expression significantly increased in a manner consistent with disease progression: the median H-score was = 0.5 in normal juxtatumoral cells,=1 in tumor cells of in situ compartment,=1.5 in tumor cells of invasive compartment, and = 2 in tumor cells at lymph node metastasis (<xref ref-type="fig" rid="fig7">Figure 7A,C</xref>). On the contrary, RalA expression did not change in tumor cells regardless of the in situ, invasive or metastatic localization (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). With the limitation that RalB amount does not necessarily reflect RalB activity, these results suggest that RalB might have a role in human breast cancer invasion and metastasis. Consistent with this hypothesis, RalB silencing was able to impair invasion (by Transwell invasion assay) of two triple-negative breast cancer cell lines: MDA-MB-231 (carrying the KRasG13D mutation) and BT549 (Ras wild-type) (<xref ref-type="fig" rid="fig7">Figure 7D</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>).</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.40474.021</object-id><label>Figure 7.</label><caption><title>Expression of Ral proteins in human breast cancers. Role of RalB in breast cancer invasion.</title><p>(<bold>A</bold>) Quantitative analysis of RalB protein level in patient samples of normal juxtatumural tissue (n = 298), in situ carcinoma (n = 101), invasive ductal carcinoma (n = 439) and lymph node metastasis (n = 91). Since none of the data sets passed the Shapiro-Wilk normality test, the median H-scores are displayed. Wilcoxon signed-rank tests were performed on paired (i.e. from same patient) data points: n = 73 for normal versus in situ, n = 290 for normal versus invasive, n = 63 for normal versus metastasis, n = 99 for in situ versus invasive, n = 29 for in situ versus metastasis, n = 85 for invasive versus metastasis. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant. (<bold>B</bold>) Quantitative analysis of RalA protein level in patient samples of normal juxtatumural tissue (n = 371), in situ carcinoma (n = 144), invasive ductal carcinoma (n = 462) and lymph node metastasis (n = 87). Since none of the data sets passed the Shapiro-Wilk normality test, the median H-scores are displayed. Wilcoxon signed-rank tests were performed on paired (i.e. from same patient) data points: n = 129 for normal versus in situ, n = 368 for normal versus invasive, n = 69 for normal versus metastasis, n = 142 for in situ versus invasive, n = 39 for in situ versus metastasis, n = 83 for invasive versus metastasis. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant. (<bold>C</bold>) Representative RalB immunostaining in the different breast cancer compartments. Scale bar, 250 µm. (<bold>D</bold>) Invasion of human breast cancer cells requires RalB, regardless of Ras mutational status. MDA-MB-231 cells (carrying the KRasG13D mutation) and BT549 cells (Ras wild-type) were transfected with the indicated siRNAs and subjected to Transwell invasion assay. Graph shows the mean ±SEM. Each dot represents one experiment. For statistics one-way ANOVA test was used. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001. ns not-significant. Legends for figure supplements.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig7-v3"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.40474.022</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Ral proteins and breast cancers.</title><p>(<bold>A</bold>) Representative staining scores for RalB and RalA on human invasive breast carcinoma. Ral proteins are stained brown (DiAminoBenzidine) and cell nuclei are stained blue (hematoxylin). Scale bar, 250 µm. (<bold>B</bold>) RalB protein level in invasive ductal carcinoma, according to the molecular breast cancer subtypes classification. Since none of the data sets passed the Shapiro-Wilk normality test, the median H-scores are displayed. Mann-Whitney statistical tests were performed. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant. (<bold>C</bold>) RalA protein level in invasive ductal carcinoma, according to the molecular breast cancer subtypes classification. Since none of the data sets passed the Shapiro-Wilk normality test, the median H-scores are displayed. Mann-Whitney statistical tests were performed. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns not-significant. (<bold>D</bold>) Validation of RalB depletions in MDA-MB-231 and BT549 cells. Representative western blots from cell lysates of cells treated with the indicated siRNA. GAPDH is used as loading control. Quantifications of RalB depletion efficiencies, calculated as Ral/GAPDH ratio and normalized for siControl condition, are shown below the WBs.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-40474-fig7-figsupp1-v3"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Collectively our findings established the utter relevance of the activation of RalB to promote invasion. By exploiting optogenetics to study causality, we showed that not only RalB was permissive for protrusion formation and invasion, but it was instructive in absence of any oncogenic mutation. Moreover, we provide a detailed molecular model of how the Ras-RalB signaling axis governs cell invasion (<xref ref-type="fig" rid="fig6">Figure 6D</xref>): active Ras binds and recruits the two RalGEFs RGL1 and RGL2, which activate RalB; activated RalB binds to the exocyst complex, promoting its assembly (<xref ref-type="bibr" rid="bib29">Moskalenko et al., 2003</xref>) and recruitment to the leading edge (<xref ref-type="bibr" rid="bib40">Rossé et al., 2006</xref>); by its direct association with the WRC complex (<xref ref-type="bibr" rid="bib4">Biondini et al., 2016</xref>), exocyst drives WRC to the leading edge, where WRC stimulates actin polymerization, protrusion formation, motility and invasion.</p><p>Unexpectedly, using the model of isogenic cell lines HEK-HT and HEK-HT-H-RasV12, we found that hyper-activations of MAP kinase and PI3 kinase pathways were not required for Ras-driven invasion. A huge previous literature had undoubtedly shown that MAPK and PI3K are involved in migration and invasion of various normal and cancer cell models (<xref ref-type="bibr" rid="bib20">Keely et al., 1997</xref>; <xref ref-type="bibr" rid="bib22">Klemke et al., 1997</xref>; <xref ref-type="bibr" rid="bib50">Ward et al., 2001</xref>; <xref ref-type="bibr" rid="bib17">Janda et al., 2002</xref>; <xref ref-type="bibr" rid="bib5">Campbell et al., 2007</xref>). However we speculate that this could not be the case in specific, relevant cellular contexts, such as the HEK-HT-H-RasV12 cells in which the RalB pathway appears to be the dominant driver of invasion down-stream oncogenic Ras. In support of this hypothesis, in a panel of pancreatic cell lines, Ral pathway was found to be more commonly activated as compared to MAPK and PI3K, since abnormally high Ral-GTP levels were much more frequent than abnormally high levels of phosphorylated ERK1/2 or phosphorylated AKT (<xref ref-type="bibr" rid="bib23">Lim et al., 2005</xref>).</p><p>In human cancer contexts, the contribution of Ral pathway activation is likely still under-estimated. Even though genetic alterations in Ral genes are rare events in human cancers, occurring in only 1.5% to 2% of patient cases considering a variety of cancer types, alterations in genes coding for Ral regulators in human tumors are not uncommon. Notably, RGL1 and RalGPS1 are found amplified in 11% of breast cancer patients, meanwhile RalGAPA1, RalGAPA2 and RalGAPB are altered in 14%, 8% and 6% of lung cancer patients, respectively (cbioportal bioinformatics platform) (<xref ref-type="bibr" rid="bib11">Gao et al., 2013</xref>), consistent with the notion that dysregulation of Ral might be important for oncogenesis or tumor progression.</p><p>In almost all cancer types examined (pancreas, colon, lung, bladder, prostate, melanoma), increased overexpression and/or activation of both RalA and RalB have been observed in patient tumor samples compared with normal tissues, regardless of their Ras mutation status (<xref ref-type="bibr" rid="bib54">Yan and Theodorescu, 2018</xref>). Moreover, Ral-GTP level were found elevated in various tumor-derived cell lines harboring different Ras status, including pancreas (<xref ref-type="bibr" rid="bib23">Lim et al., 2005</xref>), colon (<xref ref-type="bibr" rid="bib27">Martin et al., 2011</xref>), bladder (<xref ref-type="bibr" rid="bib42">Saito et al., 2013</xref>), liver (<xref ref-type="bibr" rid="bib9">Ezzeldin et al., 2014</xref>), lung (<xref ref-type="bibr" rid="bib26">Male et al., 2012</xref>) and brain (<xref ref-type="bibr" rid="bib13">Ginn et al., 2016</xref>). The only exception so far is squamous cell carcinoma (SCC), where RalA was found to suppress rather than promote tumor progression (<xref ref-type="bibr" rid="bib45">Sowalsky et al., 2010</xref>).</p><p>In this work we examined Ral protein expression in patient breast tumor samples and we found overexpression of both RalA and RalB as compared to normal breast tissues, therefore adding breast cancers to the list of human cancers with potential overstimulation of Ral pathway. Very interestingly, RalB (but not RalA) protein expression increased in a manner consistent with disease progression (normal &lt; in situ &lt; invasive &lt; metastatic tissues), supporting once more a crucial role for RalB in cancer invasion and metastasis.</p><p>In conclusion, we propose that the pharmacological inhibition of the here established Ras-RGL1/2-RalB-exocyst-WRC pathway holds promises as anticancer strategy and definitely warrants further investigations.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture and transfection</title><p>Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mM glutamine, penicillin, streptomycin, 10% fetal bovine serum. All cell lines were systematically tested to exclude mycoplasma contamination using a qPCR-based method (VenorGem Classic, BioValley) and authenticated by SRT profiling (GenePrint 10 system, Promega). See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> for detailed information and selection antibiotics. Transient DNA transfections were performed with Lipofectamine Plus reagents (Invitrogen) or JetPRIME (Polyplus). Transient double siRNA and DNA transfections were performed with RNAiMAX (Invitrogen) and JetPEI (Polyplus). See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for plasmid and siRNA sequences used in this work.</p></sec><sec id="s4-2"><title>Lentiviral transduction and cell sorting</title><p>All cells lines stably expressing the optogenetic dimerizing system were generated from HEK-HT cell lines via infection using lentiviruses. For viral production, 293 T cells were transfected with Lipofectamine 2000 (Invitrogen) with pHR-CRY2 or pLVX viral vectors along with lentiviral packaging plasmid (psPAX2) and VSVG expression vector (pCMV-VSV-G). Viral supernatant was harvested at 72 hr post-transfection, filtered, and added to the recipient cell lines for 24 hr with 6 μg/ml polybrene (# 107689, Sigma-Aldrich). Cells were sorted for co-expression of the fluorescent constructs by cell sorting on a BD FacsAria II (BD Bioscience, Flow Cytometry Core Facility Institut Curie), and cell populations were used in bulk.</p></sec><sec id="s4-3"><title>Live cell imaging</title><p>For imaging cells were plated on 25 mm glass coverslips, pre-coated with 120 µg/mL of collagen type I of rat-tail (Institut de Biotechnologie Jacques Boy), and placed in an observation chamber (Pecon, Meyer Instruments). Imaging was performed at 37°C and 5% CO2 in a heating chamber (Pecon, Meyer Instruments) on an inverted microscope Olympus IX71 equipped with a 100X objective with NA 1.45. The microscope was controlled with the software Metamorph (Molecular Devices). Differential interference contrast (DIC) imaging was performed with a far-red filter (cutoff 550 nm, BLP01-635R-25, Semrock) in the illumination path to avoid CRY2 activation. Total internal reflection fluorescence (TIRF) images were acquired using an azimuthal TIRF module (ilas2, Roper Scientific). Localized stimulation was performed with the FRAP system at low laser power (~5%) with both 491 nm and 401 nm wavelength light lasers (Stradus), 2–3 100 ms pulses, every 10–15 s. Imaging of Cherry and iRFP was done with 561 nm and 642 nm laser (Stradus), respectively. For image processing and data analysis, after background subtraction, the mean fluorescence over the time inside the blue light activated region (ROI) was measured using Metamorph software. The mCherry and iRFP recruitment curves obtained from TIRF images were expressed as fold increase of fluorescence: the value of fluorescence for each time point was normalized by the pre-illumination fluorescence (mean of the first frames without light activation). For cell edge morphodynamics and recruitment analysis, a custom-built ImageJ plugin, named ‘Recruitment Edge Dynamics’, was used (<xref ref-type="bibr" rid="bib35">Paul-Gilloteaux et al., 2018</xref>).</p></sec><sec id="s4-4"><title>Transwell invasion assay</title><p>The Transwell insert consisted in a porous membrane (8 µm pore size) with on top a thin layer of matrigel matrix that mimics the extracellular matrix (#354483, BD Biosciences). Prior to seeding in the Transwell chambers, cells were starved overnight in DMEM with 0.2% serum. 100,000 cells per well were seeded on the top of the insert in 0.2% serum medium, while 10% serum medium was placed in the well below, to create a chemoattractant gradient. After 6 hr of incubation at 37°C and 5% CO<sub>2</sub>, the insert was washed with PBS, non-invasive cells on the top of the insert were removed with a cotton swab. The cells that did invade on the bottom were fixed with 4% PFA, permeabilized with 0.5% NP-40 and incubated with 5 mg/ml DAPI to stain the nuclei. The porous membranes were cut out and mounted on slides using ProLong Gold antifade reagent (Invitrogen). Cell nuclei were imaged using an epifluorescence a Zeiss Axioplan microscope (10X objective), images were acquired with a Coolsnap HQ2 camera (Roper Scientific) and counted using ImageJ plugin ‘Cell Counter’. The Invasion index is calculated from the mean of all the replicates per each condition, normalized on the mean of the control per each experiment. For Transwell coupled with optogenetic, each well was illuminated with an independent LED using a custom-made illumination device consisting of an array of 5 mm blue LEDs (480 nm, 12 cd, 30°) driven by an Arduino Due micro-controller and delivering 3.5 mW each. Blue light was administered continuously from the bottom of the Transwell plate for the whole duration of the experiment (6 hr).</p></sec><sec id="s4-5"><title>Inverted invasion assay</title><p>Inverse invasion assays were performed accordingly to a previously published protocol (<xref ref-type="bibr" rid="bib19">Kajiho et al., 2016</xref>), but using a collagen gel instead of Matrigel. An ice-cold gel preparation of bovine collagen type I (#5005-B, Advanced Biomatrix) at a final concentration of 2.3 mg/mL, in MEM medium containing 0.28% NaHCO3 (pH = 8), was incubated 2.5 hr at 4°C (nucleation step), pipetted into 12-well 8-μm-pore-diameter transwells (#353182, Corning) (230 μm gel preparation per insert), inserted into a 12-well tissue culture plate, and incubated at 37°C for 1 hr (polymerization step). The transwells were then inverted, 4 × 10<sup>4</sup> cells were seeded on the underside of the porous membrane, and placed in 6-well plate for 2 hr (cell attachment step). The transwells were inverted back, washed 3 times with 1 ml of serum-free medium, and placed in 1.5 ml of serum-free medium inside a 12-well plate (lower chamber); 230 µl of 10% FBS-DMEM supplemented with 25 ng/ml EGF were added inside the transwell (upper chamber). The cells were then allowed to invade upward into the bovine collagen and toward the gradient of serum/EGF for 4 days at 37°C and 5% CO<sub>2</sub>. Cells were live stained with CellTrace yellow (Thermofisher) for 1 hr at 37°C and rapidly imaged by confocal microscopy (Zeiss LSM880, 10x objective, excitation at 545 nm and emission at 605 nm). Optical sections were captured at 5 µm intervals, starting from the underside of the transwell membrane and moving upward in the direction of cell invasion. The resulting fluorescence images were quantified using ImageJ software. For each independent experiment, data were generated from two duplicate transwells, and optical sections were acquired from two areas of each transwell.</p></sec><sec id="s4-6"><title>Immunoblotting, Immunofluorescence, RT-qPCR</title><p>For immunoblotting, cells were lysed in RIPA buffer (150 mM NaCl, 2 mM MgCl, 2 mM CaCl2, 0.5% NaDOC, 1% NP40, 0.1% SDS, 10% Glycerol, 50 mM Tris-HCL pH 8.0) containing 2 mM Na3VO4, 10 mM NaF, 1 mM DTT and a protease inhibitor mixture (#0589291001, Roche). Equal amounts of protein were diluted in 4x Laemmli buffer and resolved by SDS-PAGE. Proteins were transferred to 0.45 μm nitrocellulose membranes (Whatman) by wet transfer and blocked with 3% BSA in TBS/0.05% Tween-20 for 30 min. Primary antibodies were: mouse anti-RalA (#610222, BD Transduction Laboratories, dilution 1:1000); rabbit anti-RalB (#3523, Cell Signaling, dilution 1:500); mouse anti AKT(pan) (#2920, Cell Signaling, dilution 1:1000); rabbit anti p-AKT(Ser437)(#9271, Cell Signaling, dilution 1:1000). Protein levels were detected using LICOR Odyssey Infrared Imaging System (LI-COR Biosciences) upon incubation with IRDye secondary antibodies for 1 hr at room temperature.</p><p>For immunofluorescence, cells were cultured on coverslips, fixed with 4% paraformaldehyde, quenched with 1M Glycine solution, permeabilized with 0.1% of Triton-100X, incubated with 4% FBS +1% BSA blocking solution, then with primary and secondary antibodies, every step being in PBS buffer. Primary antibodies were: mouse anti-RalB (#WH0005899M4, clone 4D1, Sigma-Aldrich, dilution 1:200), mouse anti-RGL2 (#H00005863-M02, clone 4D10, Novus biologicals, dilution 1:200). For RT-qPCR analysis, total RNA was extracted using RNaeasy Plus Mini kit (Quigen). Retrotranscription and amplification were obtained using the iScript cDNA synthesis kit (BioRad), the SYBR Green Master Mix kit or TaqMan (Applied Biosystems) on the ABI Prism7900 SequenceDetection System (Perkin-Elmer Applied Biosystems). See <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for the RT-qPCR primers.</p></sec><sec id="s4-7"><title>Rac1 and RalB activity measurements</title><p>Rac1 activity was measured using the ‘Rac1 Pull-down Activation Assay Biochem Kit’ (# BK035, Cytoskeleton), which is based on beads-coupled GST-Pak1GBD. A similar pull-down assay was used for RalB activity but using home-made beads-coupled GST-Sec5GBD. For RalB activity measurement by FRET, cells were transfected with a validated FRET-based RalB biosensor (<xref ref-type="bibr" rid="bib28">Martin et al., 2014</xref>) and imaged with an Olympus IX71 microscope equipped with a FRET filter set (86002v1JP4, Chroma Technology) and a 63x oil-immersion objective. YFP/CFP images were generated using Metamorph and ImageJ software.</p></sec><sec id="s4-8"><title>Size exclusion chromatography</title><p>Cells were washed in ice‐cold PBS and lysed in 30 mM Tris (pH 7.2), 150 mM NaCl and 1% CHAPS. Lysates were clarified by centrifugation at 40 000 r.p.m. for 30 min. Protein was fractionated on a Superose 6 10/300 GL Increase (GE Healthcare Life Sciences) connected to an ÄKTA pure chromatography system (GE Healthcare Life Sciences, Protein Expression and Purification Core Facility, Institut Curie). The column was eluted with 30 mM Tris (pH 7.2), 150 mM NaCl and 1% CHAPS at 0.5 ml/min and 0.5 ml fractions were collected. Prior to SDS-PAGE analysis, proteins were concentrated with 20% Trichloroacetic Acid Protein (TCA), washed in Acetone and resuspended in Laemmli buffer.</p></sec><sec id="s4-9"><title>Breast cancer samples</title><p>Primary tumors and lymph nodes were surgically removed before any radiation, hormonal or chemo-therapy, using a cohort of patients (n = 649) treated at the Institut Curie from 2005 to 2006. In this cohort, 502 invasive ductal carcinomas were selected for Ral detection; after discarding the samples with staining problems, the final numbers of analyzed cases were n = 466 for RalA and n = 448 for RalB. Tissue microarrays (TMA) consisted of replicated tumor cores (1 mm diameter) selected from whole-tumor tissue sections and a matched tissue core from adjacent non-tumoral breast epithelium (referred to as normal breast tissue). Immunoistochemistry (IHC) staining was performed using a Dako Autostainer Plus according to previously published protocols (<xref ref-type="bibr" rid="bib25">Lodillinsky et al., 2016</xref>). Antibodies were: anti-RalB (#WH0005899M4, clone 4D1, Sigma-Aldrich), anti-RalA (#610222, BD Transduction Laboratories). H-scores were calculated using the following formula: stained cell percentage x stain intensity/100.</p><p>Analysis of human samples was performed in accordance with the French Bioethics Law 2004–800, the French National Institute of Cancer (INCa) Ethics Charter, and after approval by the Institut Curie review board and ethics committee (Comité de Pilotage du Groupe Sein) that waived the need for written informed consent from the participants. Women were informed of the research use of their tissues. Data were analyzed anonymously.</p></sec><sec id="s4-10"><title>Statistics</title><p>Results are shown as mean ± standard deviation (SD) or standard error of the mean (SEM). Statistical analysis was performed using Graphpad Prism (v5.0) and R Software v.3.3.2 (<xref ref-type="bibr" rid="bib36">R Core Team, 2016</xref>). Comparisons between two groups were assessed using Student t-test. Comparisons between more than two groups were assessed using one-way ANOVA test. Comparisons between paired data were assessed using Wilcoxon signed-rank test. For breast cancer H-score analysis, Shapiro-Wilk normality test and non-parametric Mann-Whitney tests and Wilcoxon signed-rank test for paired data were used. p values less than 0.05 were considered significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the staff of Flow Cytometry Core Facility of Institut Curie for their excellent assistance, the Cell and Tissue Imaging (PICT-IBiSA), Institut Curie, member of the French National Research Infrastructure France-BioImaging (ANR10-INBS-04), Chiara Vicario for discussion and analysis help, and Hiroaki Kajiho and Giorgio Scita for very kindly sharing their detailed protocols. This work was supported by Fondation ARC pour la Recherche sur le Cancer (PJA 20151203371 to MCP, fellowship to GZ), Institut national de la Santé et de la Recherche médicale (INSERM ITMO Plan Cancer 2014–2018, PC201530 to MC and MCP), Association Christelle Bouillot, French National Research Agency (ANR) Paris-Science-Lettres Program (ANR-10-IDEX-0001–02 PSL).</p> </ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Validation, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Writing—review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Supervision, Funding acquisition, Writing—review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Supervision, Funding acquisition, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.40474.023</object-id><label>Supplementary file 1.</label><caption><title>List of cell lines</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40474-supp1-v3.docx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.40474.024</object-id><label>Supplementary file 2.</label><caption><title>List of plasmids</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40474-supp2-v3.docx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.40474.025</object-id><label>Supplementary file 3.:</label><caption><title>List of siRNAs</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40474-supp3-v3.docx"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.40474.026</object-id><label>Supplementary file 4.</label><caption><title>List of primers</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-40474-supp4-v3.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.40474.027</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-40474-transrepform-v3.docx"/></supplementary-material><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alekhina</surname> <given-names>O</given-names></name><name><surname>Burstein</surname> <given-names>E</given-names></name><name><surname>Billadeau</surname> <given-names>DD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cellular functions of WASP family proteins at a glance</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>2235</fpage><lpage>2241</lpage><pub-id pub-id-type="doi">10.1242/jcs.199570</pub-id><pub-id pub-id-type="pmid">28646090</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettoun</surname> <given-names>A</given-names></name><name><surname>Joffre</surname> <given-names>C</given-names></name><name><surname>Zago</surname> <given-names>G</given-names></name><name><surname>Surdez</surname> <given-names>D</given-names></name><name><surname>Vallerand</surname> <given-names>D</given-names></name><name><surname>Gundogdu</surname> <given-names>R</given-names></name><name><surname>Sharif</surname> <given-names>AA</given-names></name><name><surname>Gomez</surname> <given-names>M</given-names></name><name><surname>Cascone</surname> <given-names>I</given-names></name><name><surname>Meunier</surname> <given-names>B</given-names></name><name><surname>White</surname> <given-names>MA</given-names></name><name><surname>Codogno</surname> <given-names>P</given-names></name><name><surname>Parrini</surname> <given-names>MC</given-names></name><name><surname>Camonis</surname> <given-names>JH</given-names></name><name><surname>Hergovich</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mitochondrial clearance by the STK38 kinase supports oncogenic Ras-induced cell transformation</article-title><source>Oncotarget</source><volume>7</volume><fpage>44142</fpage><lpage>44160</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9875</pub-id><pub-id pub-id-type="pmid">27283898</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondini</surname> <given-names>M</given-names></name><name><surname>Duclos</surname> <given-names>G</given-names></name><name><surname>Meyer-Schaller</surname> <given-names>N</given-names></name><name><surname>Silberzan</surname> <given-names>P</given-names></name><name><surname>Camonis</surname> <given-names>J</given-names></name><name><surname>Parrini</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>RalB regulates contractility-driven cancer dissemination upon TGFβ stimulation via the RhoGEF GEF-H1</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>11759</elocation-id><pub-id pub-id-type="doi">10.1038/srep11759</pub-id><pub-id pub-id-type="pmid">26152517</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biondini</surname> <given-names>M</given-names></name><name><surname>Sadou-Dubourgnoux</surname> <given-names>A</given-names></name><name><surname>Paul-Gilloteaux</surname> <given-names>P</given-names></name><name><surname>Zago</surname> <given-names>G</given-names></name><name><surname>Arslanhan</surname> <given-names>MD</given-names></name><name><surname>Waharte</surname> <given-names>F</given-names></name><name><surname>Formstecher</surname> <given-names>E</given-names></name><name><surname>Hertzog</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Guerois</surname> <given-names>R</given-names></name><name><surname>Gautreau</surname> <given-names>A</given-names></name><name><surname>Scita</surname> <given-names>G</given-names></name><name><surname>Camonis</surname> <given-names>J</given-names></name><name><surname>Parrini</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct interaction between exocyst and Wave complexes promotes cell protrusions and motility</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>3756</fpage><lpage>3769</lpage><pub-id pub-id-type="doi">10.1242/jcs.187336</pub-id><pub-id pub-id-type="pmid">27591259</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname> <given-names>PM</given-names></name><name><surname>Groehler</surname> <given-names>AL</given-names></name><name><surname>Lee</surname> <given-names>KM</given-names></name><name><surname>Ouellette</surname> <given-names>MM</given-names></name><name><surname>Khazak</surname> <given-names>V</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling</article-title><source>Cancer Research</source><volume>67</volume><fpage>2098</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3752</pub-id><pub-id pub-id-type="pmid">17332339</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceriani</surname> <given-names>M</given-names></name><name><surname>Scandiuzzi</surname> <given-names>C</given-names></name><name><surname>Amigoni</surname> <given-names>L</given-names></name><name><surname>Tisi</surname> <given-names>R</given-names></name><name><surname>Berruti</surname> <given-names>G</given-names></name><name><surname>Martegani</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Functional analysis of RalGPS2, a murine guanine nucleotide exchange factor for RalA GTPase</article-title><source>Experimental Cell Research</source><volume>313</volume><fpage>2293</fpage><lpage>2307</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2007.03.016</pub-id><pub-id pub-id-type="pmid">17462626</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>XJ</given-names></name><name><surname>Squarr</surname> <given-names>AJ</given-names></name><name><surname>Stephan</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>B</given-names></name><name><surname>Higgins</surname> <given-names>TE</given-names></name><name><surname>Barry</surname> <given-names>DJ</given-names></name><name><surname>Martin</surname> <given-names>MC</given-names></name><name><surname>Rosen</surname> <given-names>MK</given-names></name><name><surname>Bogdan</surname> <given-names>S</given-names></name><name><surname>Way</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ena/VASP proteins cooperate with the WAVE complex to regulate the actin cytoskeleton</article-title><source>Developmental Cell</source><volume>30</volume><fpage>569</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2014.08.001</pub-id><pub-id pub-id-type="pmid">25203209</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>AD</given-names></name><name><surname>Fesik</surname> <given-names>SW</given-names></name><name><surname>Kimmelman</surname> <given-names>AC</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Drugging the undruggable RAS: Mission possible?</article-title><source>Nature Reviews Drug Discovery</source><volume>13</volume><fpage>828</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/nrd4389</pub-id><pub-id pub-id-type="pmid">25323927</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ezzeldin</surname> <given-names>M</given-names></name><name><surname>Borrego-Diaz</surname> <given-names>E</given-names></name><name><surname>Taha</surname> <given-names>M</given-names></name><name><surname>Esfandyari</surname> <given-names>T</given-names></name><name><surname>Wise</surname> <given-names>AL</given-names></name><name><surname>Peng</surname> <given-names>W</given-names></name><name><surname>Rouyanian</surname> <given-names>A</given-names></name><name><surname>Asvadi Kermani</surname> <given-names>A</given-names></name><name><surname>Soleimani</surname> <given-names>M</given-names></name><name><surname>Patrad</surname> <given-names>E</given-names></name><name><surname>Lialyte</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Williamson</surname> <given-names>S</given-names></name><name><surname>Abdulkarim</surname> <given-names>B</given-names></name><name><surname>Olyaee</surname> <given-names>M</given-names></name><name><surname>Farassati</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC)</article-title><source>Molecular Oncology</source><volume>8</volume><fpage>1043</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.03.020</pub-id><pub-id pub-id-type="pmid">24785097</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferro</surname> <given-names>E</given-names></name><name><surname>Magrini</surname> <given-names>D</given-names></name><name><surname>Guazzi</surname> <given-names>P</given-names></name><name><surname>Fischer</surname> <given-names>TH</given-names></name><name><surname>Pistolesi</surname> <given-names>S</given-names></name><name><surname>Pogni</surname> <given-names>R</given-names></name><name><surname>White</surname> <given-names>GC</given-names></name><name><surname>Trabalzini</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>G-protein binding features and regulation of the RalGDS family member, RGL2</article-title><source>Biochemical Journal</source><volume>415</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1042/BJ20080255</pub-id><pub-id pub-id-type="pmid">18540861</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Aksoy</surname> <given-names>BA</given-names></name><name><surname>Dogrusoz</surname> <given-names>U</given-names></name><name><surname>Dresdner</surname> <given-names>G</given-names></name><name><surname>Gross</surname> <given-names>B</given-names></name><name><surname>Sumer</surname> <given-names>SO</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Jacobsen</surname> <given-names>A</given-names></name><name><surname>Sinha</surname> <given-names>R</given-names></name><name><surname>Larsson</surname> <given-names>E</given-names></name><name><surname>Cerami</surname> <given-names>E</given-names></name><name><surname>Sander</surname> <given-names>C</given-names></name><name><surname>Schultz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautreau</surname> <given-names>A</given-names></name><name><surname>Ho</surname> <given-names>HY</given-names></name><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Steen</surname> <given-names>H</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Kirschner</surname> <given-names>MW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Purification and architecture of the ubiquitous Wave complex</article-title><source>PNAS</source><volume>101</volume><fpage>4379</fpage><lpage>4383</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400628101</pub-id><pub-id pub-id-type="pmid">15070726</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginn</surname> <given-names>KF</given-names></name><name><surname>Fangman</surname> <given-names>B</given-names></name><name><surname>Terai</surname> <given-names>K</given-names></name><name><surname>Wise</surname> <given-names>A</given-names></name><name><surname>Ziazadeh</surname> <given-names>D</given-names></name><name><surname>Shah</surname> <given-names>K</given-names></name><name><surname>Gartrell</surname> <given-names>R</given-names></name><name><surname>Ricke</surname> <given-names>B</given-names></name><name><surname>Kimura</surname> <given-names>K</given-names></name><name><surname>Mathur</surname> <given-names>S</given-names></name><name><surname>Borrego-Diaz</surname> <given-names>E</given-names></name><name><surname>Farassati</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RalA is overactivated in medulloblastoma</article-title><source>Journal of Neuro-Oncology</source><volume>130</volume><fpage>99</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1007/s11060-016-2236-4</pub-id><pub-id pub-id-type="pmid">27566179</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name><name><surname>Lundberg</surname> <given-names>AS</given-names></name><name><surname>Beijersbergen</surname> <given-names>RL</given-names></name><name><surname>Brooks</surname> <given-names>MW</given-names></name><name><surname>Weinberg</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Creation of human tumour cells with defined genetic elements</article-title><source>Nature</source><volume>400</volume><fpage>464</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/22780</pub-id><pub-id pub-id-type="pmid">10440377</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamad</surname> <given-names>NM</given-names></name><name><surname>Elconin</surname> <given-names>JH</given-names></name><name><surname>Karnoub</surname> <given-names>AE</given-names></name><name><surname>Bai</surname> <given-names>W</given-names></name><name><surname>Rich</surname> <given-names>JN</given-names></name><name><surname>Abraham</surname> <given-names>RT</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Distinct requirements for Ras oncogenesis in human versus mouse cells</article-title><source>Genes &amp; Development</source><volume>16</volume><fpage>2045</fpage><lpage>2057</lpage><pub-id pub-id-type="doi">10.1101/gad.993902</pub-id><pub-id pub-id-type="pmid">12183360</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>CH</given-names></name><name><surname>Tang</surname> <given-names>M</given-names></name><name><surname>Shi</surname> <given-names>C</given-names></name><name><surname>Iglesias</surname> <given-names>PA</given-names></name><name><surname>Devreotes</surname> <given-names>PN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An excitable signal integrator couples to an idling cytoskeletal oscillator to drive cell migration</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>1307</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1038/ncb2859</pub-id><pub-id pub-id-type="pmid">24142103</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janda</surname> <given-names>E</given-names></name><name><surname>Lehmann</surname> <given-names>K</given-names></name><name><surname>Killisch</surname> <given-names>I</given-names></name><name><surname>Jechlinger</surname> <given-names>M</given-names></name><name><surname>Herzig</surname> <given-names>M</given-names></name><name><surname>Downward</surname> <given-names>J</given-names></name><name><surname>Beug</surname> <given-names>H</given-names></name><name><surname>Grünert</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways</article-title><source>The Journal of cell biology</source><volume>156</volume><fpage>299</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1083/jcb.200109037</pub-id><pub-id pub-id-type="pmid">11790801</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jänne</surname> <given-names>PA</given-names></name><name><surname>Shaw</surname> <given-names>AT</given-names></name><name><surname>Pereira</surname> <given-names>JR</given-names></name><name><surname>Jeannin</surname> <given-names>G</given-names></name><name><surname>Vansteenkiste</surname> <given-names>J</given-names></name><name><surname>Barrios</surname> <given-names>C</given-names></name><name><surname>Franke</surname> <given-names>FA</given-names></name><name><surname>Grinsted</surname> <given-names>L</given-names></name><name><surname>Zazulina</surname> <given-names>V</given-names></name><name><surname>Smith</surname> <given-names>P</given-names></name><name><surname>Smith</surname> <given-names>I</given-names></name><name><surname>Crinò</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study</article-title><source>The Lancet Oncology</source><volume>14</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70489-8</pub-id><pub-id pub-id-type="pmid">23200175</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajiho</surname> <given-names>H</given-names></name><name><surname>Kajiho</surname> <given-names>Y</given-names></name><name><surname>Frittoli</surname> <given-names>E</given-names></name><name><surname>Confalonieri</surname> <given-names>S</given-names></name><name><surname>Bertalot</surname> <given-names>G</given-names></name><name><surname>Viale</surname> <given-names>G</given-names></name><name><surname>Di Fiore</surname> <given-names>PP</given-names></name><name><surname>Oldani</surname> <given-names>A</given-names></name><name><surname>Garre</surname> <given-names>M</given-names></name><name><surname>Beznoussenko</surname> <given-names>GV</given-names></name><name><surname>Palamidessi</surname> <given-names>A</given-names></name><name><surname>Vecchi</surname> <given-names>M</given-names></name><name><surname>Chavrier</surname> <given-names>P</given-names></name><name><surname>Perez</surname> <given-names>F</given-names></name><name><surname>Scita</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>RAB2A controls MT1-MMP endocytic and E-cadherin polarized Golgi trafficking to promote invasive breast cancer programs</article-title><source>EMBO reports</source><volume>17</volume><fpage>1061</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.15252/embr.201642032</pub-id><pub-id pub-id-type="pmid">27255086</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keely</surname> <given-names>PJ</given-names></name><name><surname>Westwick</surname> <given-names>JK</given-names></name><name><surname>Whitehead</surname> <given-names>IP</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Parise</surname> <given-names>LV</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K</article-title><source>Nature</source><volume>390</volume><fpage>632</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/37656</pub-id><pub-id pub-id-type="pmid">9403696</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname> <given-names>MJ</given-names></name><name><surname>Hughes</surname> <given-names>RM</given-names></name><name><surname>Peteya</surname> <given-names>LA</given-names></name><name><surname>Schwartz</surname> <given-names>JW</given-names></name><name><surname>Ehlers</surname> <given-names>MD</given-names></name><name><surname>Tucker</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Rapid blue-light-mediated induction of protein interactions in living cells</article-title><source>Nature Methods</source><volume>7</volume><fpage>973</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1524</pub-id><pub-id pub-id-type="pmid">21037589</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemke</surname> <given-names>RL</given-names></name><name><surname>Cai</surname> <given-names>S</given-names></name><name><surname>Giannini</surname> <given-names>AL</given-names></name><name><surname>Gallagher</surname> <given-names>PJ</given-names></name><name><surname>de Lanerolle</surname> <given-names>P</given-names></name><name><surname>Cheresh</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Regulation of cell motility by mitogen-activated protein kinase</article-title><source>The Journal of Cell Biology</source><volume>137</volume><fpage>481</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1083/jcb.137.2.481</pub-id><pub-id pub-id-type="pmid">9128257</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>KH</given-names></name><name><surname>Baines</surname> <given-names>AT</given-names></name><name><surname>Fiordalisi</surname> <given-names>JJ</given-names></name><name><surname>Shipitsin</surname> <given-names>M</given-names></name><name><surname>Feig</surname> <given-names>LA</given-names></name><name><surname>Cox</surname> <given-names>AD</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation of RalA is critical for Ras-induced tumorigenesis of human cells</article-title><source>Cancer Cell</source><volume>7</volume><fpage>533</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2005.04.030</pub-id><pub-id pub-id-type="pmid">15950903</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname> <given-names>KH</given-names></name><name><surname>O'Hayer</surname> <given-names>K</given-names></name><name><surname>Adam</surname> <given-names>SJ</given-names></name><name><surname>Kendall</surname> <given-names>SD</given-names></name><name><surname>Campbell</surname> <given-names>PM</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells</article-title><source>Current Biology</source><volume>16</volume><fpage>2385</fpage><lpage>2394</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.10.023</pub-id><pub-id pub-id-type="pmid">17174914</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lodillinsky</surname> <given-names>C</given-names></name><name><surname>Infante</surname> <given-names>E</given-names></name><name><surname>Guichard</surname> <given-names>A</given-names></name><name><surname>Chaligné</surname> <given-names>R</given-names></name><name><surname>Fuhrmann</surname> <given-names>L</given-names></name><name><surname>Cyrta</surname> <given-names>J</given-names></name><name><surname>Irondelle</surname> <given-names>M</given-names></name><name><surname>Lagoutte</surname> <given-names>E</given-names></name><name><surname>Vacher</surname> <given-names>S</given-names></name><name><surname>Bonsang-Kitzis</surname> <given-names>H</given-names></name><name><surname>Glukhova</surname> <given-names>M</given-names></name><name><surname>Reyal</surname> <given-names>F</given-names></name><name><surname>Bièche</surname> <given-names>I</given-names></name><name><surname>Vincent-Salomon</surname> <given-names>A</given-names></name><name><surname>Chavrier</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer</article-title><source>Oncogene</source><volume>35</volume><fpage>344</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/onc.2015.87</pub-id><pub-id pub-id-type="pmid">25893299</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Male</surname> <given-names>H</given-names></name><name><surname>Patel</surname> <given-names>V</given-names></name><name><surname>Jacob</surname> <given-names>MA</given-names></name><name><surname>Borrego-Diaz</surname> <given-names>E</given-names></name><name><surname>Wang</surname> <given-names>K</given-names></name><name><surname>Young</surname> <given-names>DA</given-names></name><name><surname>Wise</surname> <given-names>AL</given-names></name><name><surname>Huang</surname> <given-names>C</given-names></name><name><surname>Van Veldhuizen</surname> <given-names>P</given-names></name><name><surname>O'Brien-Ladner</surname> <given-names>A</given-names></name><name><surname>Williamson</surname> <given-names>SK</given-names></name><name><surname>Taylor</surname> <given-names>SA</given-names></name><name><surname>Tawfik</surname> <given-names>O</given-names></name><name><surname>Esfandyari</surname> <given-names>T</given-names></name><name><surname>Farassati</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer</article-title><source>Lung Cancer</source><volume>77</volume><fpage>252</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2012.03.007</pub-id><pub-id pub-id-type="pmid">22498113</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>TD</given-names></name><name><surname>Samuel</surname> <given-names>JC</given-names></name><name><surname>Routh</surname> <given-names>ED</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name><name><surname>Yeh</surname> <given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activation and involvement of Ral GTPases in colorectal cancer</article-title><source>Cancer Research</source><volume>71</volume><fpage>206</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1517</pub-id><pub-id pub-id-type="pmid">21199803</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname> <given-names>TD</given-names></name><name><surname>Chen</surname> <given-names>XW</given-names></name><name><surname>Kaplan</surname> <given-names>RE</given-names></name><name><surname>Saltiel</surname> <given-names>AR</given-names></name><name><surname>Walker</surname> <given-names>CL</given-names></name><name><surname>Reiner</surname> <given-names>DJ</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion</article-title><source>Molecular Cell</source><volume>53</volume><fpage>209</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.12.004</pub-id><pub-id pub-id-type="pmid">24389102</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskalenko</surname> <given-names>S</given-names></name><name><surname>Tong</surname> <given-names>C</given-names></name><name><surname>Rosse</surname> <given-names>C</given-names></name><name><surname>Mirey</surname> <given-names>G</given-names></name><name><surname>Formstecher</surname> <given-names>E</given-names></name><name><surname>Daviet</surname> <given-names>L</given-names></name><name><surname>Camonis</surname> <given-names>J</given-names></name><name><surname>White</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Ral GTPases regulate exocyst assembly through dual subunit interactions</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>51743</fpage><lpage>51748</lpage><pub-id pub-id-type="doi">10.1074/jbc.M308702200</pub-id><pub-id pub-id-type="pmid">14525976</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neel</surname> <given-names>NF</given-names></name><name><surname>Martin</surname> <given-names>TD</given-names></name><name><surname>Stratford</surname> <given-names>JK</given-names></name><name><surname>Zand</surname> <given-names>TP</given-names></name><name><surname>Reiner</surname> <given-names>DJ</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The RalGEF-Ral effector signaling network: the road less traveled for Anti-Ras drug discovery</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>275</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1177/1947601911407329</pub-id><pub-id pub-id-type="pmid">21779498</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neel</surname> <given-names>NF</given-names></name><name><surname>Rossman</surname> <given-names>KL</given-names></name><name><surname>Martin</surname> <given-names>TD</given-names></name><name><surname>Hayes</surname> <given-names>TK</given-names></name><name><surname>Yeh</surname> <given-names>JJ</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector</article-title><source>Molecular and Cellular Biology</source><volume>32</volume><fpage>1374</fpage><lpage>1386</lpage><pub-id pub-id-type="doi">10.1128/MCB.06291-11</pub-id><pub-id pub-id-type="pmid">22331470</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Hayer</surname> <given-names>KM</given-names></name><name><surname>Counter</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro</article-title><source>Methods in enzymology</source><volume>407</volume><fpage>637</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1016/S0076-6879(05)07050-3</pub-id><pub-id pub-id-type="pmid">16757358</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oxford</surname> <given-names>G</given-names></name><name><surname>Owens</surname> <given-names>CR</given-names></name><name><surname>Titus</surname> <given-names>BJ</given-names></name><name><surname>Foreman</surname> <given-names>TL</given-names></name><name><surname>Herlevsen</surname> <given-names>MC</given-names></name><name><surname>Smith</surname> <given-names>SC</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>RalA and RalB: antagonistic relatives in Cancer cell migration</article-title><source>Cancer Research</source><volume>65</volume><fpage>7111</fpage><lpage>7120</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1957</pub-id><pub-id pub-id-type="pmid">16103060</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrini</surname> <given-names>MC</given-names></name><name><surname>Sadou-Dubourgnoux</surname> <given-names>A</given-names></name><name><surname>Aoki</surname> <given-names>K</given-names></name><name><surname>Kunida</surname> <given-names>K</given-names></name><name><surname>Biondini</surname> <given-names>M</given-names></name><name><surname>Hatzoglou</surname> <given-names>A</given-names></name><name><surname>Poullet</surname> <given-names>P</given-names></name><name><surname>Formstecher</surname> <given-names>E</given-names></name><name><surname>Yeaman</surname> <given-names>C</given-names></name><name><surname>Matsuda</surname> <given-names>M</given-names></name><name><surname>Rossé</surname> <given-names>C</given-names></name><name><surname>Camonis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>SH3BP1, an exocyst-associated RhoGAP, inactivates Rac1 at the front to drive cell motility</article-title><source>Molecular Cell</source><volume>42</volume><fpage>650</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2011.03.032</pub-id><pub-id pub-id-type="pmid">21658605</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul-Gilloteaux</surname> <given-names>P</given-names></name><name><surname>Waharte</surname> <given-names>F</given-names></name><name><surname>Singh</surname> <given-names>MK</given-names></name><name><surname>Parrini</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Biologist-Friendly method to analyze Cross-Correlation between protrusion dynamics and membrane recruitment of actin regulators</article-title><source>Methods in Molecular Biology</source><volume>1749</volume><fpage>279</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7701-7_20</pub-id><pub-id pub-id-type="pmid">29526004</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><collab>R Core Team</collab></person-group><year iso-8601-date="2016">2016</year><data-title>R: A Language and environment for statistical computing</data-title><version designator="3.3.2">3.3.2</version><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name><ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebhun</surname> <given-names>JF</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Quilliam</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Identification and characterization of a new family of guanine nucleotide exchange factors for the ras-related GTPase Ral</article-title><source>Journal of Biological Chemistry</source><volume>275</volume><fpage>13406</fpage><lpage>13410</lpage><pub-id pub-id-type="doi">10.1074/jbc.C000085200</pub-id><pub-id pub-id-type="pmid">10747847</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname> <given-names>AJ</given-names></name><name><surname>Paterson</surname> <given-names>HF</given-names></name><name><surname>Johnston</surname> <given-names>CL</given-names></name><name><surname>Diekmann</surname> <given-names>D</given-names></name><name><surname>Hall</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>The small GTP-binding protein rac regulates growth factor-induced membrane ruffling</article-title><source>Cell</source><volume>70</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90164-8</pub-id><pub-id pub-id-type="pmid">1643658</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname> <given-names>AJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking</article-title><source>Trends in Cell Biology</source><volume>16</volume><fpage>522</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2006.08.006</pub-id><pub-id pub-id-type="pmid">16949823</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossé</surname> <given-names>C</given-names></name><name><surname>Hatzoglou</surname> <given-names>A</given-names></name><name><surname>Parrini</surname> <given-names>MC</given-names></name><name><surname>White</surname> <given-names>MA</given-names></name><name><surname>Chavrier</surname> <given-names>P</given-names></name><name><surname>Camonis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>RalB mobilizes the exocyst to drive cell migration</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>727</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.2.727-734.2006</pub-id><pub-id pub-id-type="pmid">16382162</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybko</surname> <given-names>VA</given-names></name><name><surname>Knizhnik</surname> <given-names>AV</given-names></name><name><surname>Komelkov</surname> <given-names>AV</given-names></name><name><surname>Aushev</surname> <given-names>VN</given-names></name><name><surname>Trukhanova</surname> <given-names>LS</given-names></name><name><surname>Tchevkina</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Different metastasis promotive potency of small G-proteins RalA and RalB in in vivo hamster tumor model</article-title><source>Cancer Cell International</source><volume>11</volume><elocation-id>22</elocation-id><pub-id pub-id-type="doi">10.1186/1475-2867-11-22</pub-id><pub-id pub-id-type="pmid">21714887</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname> <given-names>R</given-names></name><name><surname>Shirakawa</surname> <given-names>R</given-names></name><name><surname>Nishiyama</surname> <given-names>H</given-names></name><name><surname>Kobayashi</surname> <given-names>T</given-names></name><name><surname>Kawato</surname> <given-names>M</given-names></name><name><surname>Kanno</surname> <given-names>T</given-names></name><name><surname>Nishizawa</surname> <given-names>K</given-names></name><name><surname>Matsui</surname> <given-names>Y</given-names></name><name><surname>Ohbayashi</surname> <given-names>T</given-names></name><name><surname>Horiguchi</surname> <given-names>M</given-names></name><name><surname>Nakamura</surname> <given-names>T</given-names></name><name><surname>Ikeda</surname> <given-names>T</given-names></name><name><surname>Yamane</surname> <given-names>K</given-names></name><name><surname>Nakayama</surname> <given-names>E</given-names></name><name><surname>Nakamura</surname> <given-names>E</given-names></name><name><surname>Toda</surname> <given-names>Y</given-names></name><name><surname>Kimura</surname> <given-names>T</given-names></name><name><surname>Kita</surname> <given-names>T</given-names></name><name><surname>Ogawa</surname> <given-names>O</given-names></name><name><surname>Horiuchi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer</article-title><source>Oncogene</source><volume>32</volume><fpage>894</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1038/onc.2012.101</pub-id><pub-id pub-id-type="pmid">22450745</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sells</surname> <given-names>MA</given-names></name><name><surname>Knaus</surname> <given-names>UG</given-names></name><name><surname>Bagrodia</surname> <given-names>S</given-names></name><name><surname>Ambrose</surname> <given-names>DM</given-names></name><name><surname>Bokoch</surname> <given-names>GM</given-names></name><name><surname>Chernoff</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells</article-title><source>Current Biology</source><volume>7</volume><fpage>202</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(97)70091-5</pub-id><pub-id pub-id-type="pmid">9395435</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simanshu</surname> <given-names>DK</given-names></name><name><surname>Nissley</surname> <given-names>DV</given-names></name><name><surname>McCormick</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>RAS proteins and their regulators in human disease</article-title><source>Cell</source><volume>170</volume><fpage>17</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.009</pub-id><pub-id pub-id-type="pmid">28666118</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowalsky</surname> <given-names>AG</given-names></name><name><surname>Alt-Holland</surname> <given-names>A</given-names></name><name><surname>Shamis</surname> <given-names>Y</given-names></name><name><surname>Garlick</surname> <given-names>JA</given-names></name><name><surname>Feig</surname> <given-names>LA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RalA suppresses early stages of Ras-induced squamous cell carcinoma progression</article-title><source>Oncogene</source><volume>29</volume><fpage>45</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.307</pub-id><pub-id pub-id-type="pmid">19802010</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname> <given-names>A</given-names></name><name><surname>Ohba</surname> <given-names>Y</given-names></name><name><surname>Kurokawa</surname> <given-names>K</given-names></name><name><surname>Matsuda</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>RalA activation at nascent lamellipodia of epidermal growth factor-stimulated Cos7 cells and migrating Madin-Darby canine kidney cells</article-title><source>Molecular Biology of the Cell</source><volume>15</volume><fpage>2549</fpage><lpage>2557</lpage><pub-id pub-id-type="doi">10.1091/mbc.e03-11-0857</pub-id><pub-id pub-id-type="pmid">15034142</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tischer</surname> <given-names>D</given-names></name><name><surname>Weiner</surname> <given-names>OD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Illuminating cell signalling with optogenetic tools</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>15</volume><fpage>551</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/nrm3837</pub-id><pub-id pub-id-type="pmid">25027655</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toettcher</surname> <given-names>JE</given-names></name><name><surname>Weiner</surname> <given-names>OD</given-names></name><name><surname>Lim</surname> <given-names>WA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Using optogenetics to interrogate the dynamic control of signal transmission by the Ras/Erk module</article-title><source>Cell</source><volume>155</volume><fpage>1422</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.004</pub-id><pub-id pub-id-type="pmid">24315106</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valon</surname> <given-names>L</given-names></name><name><surname>Etoc</surname> <given-names>F</given-names></name><name><surname>Remorino</surname> <given-names>A</given-names></name><name><surname>di Pietro</surname> <given-names>F</given-names></name><name><surname>Morin</surname> <given-names>X</given-names></name><name><surname>Dahan</surname> <given-names>M</given-names></name><name><surname>Coppey</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Predictive spatiotemporal manipulation of signaling perturbations using optogenetics</article-title><source>Biophysical Journal</source><volume>109</volume><fpage>1785</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2015.08.042</pub-id><pub-id pub-id-type="pmid">26536256</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Woodhouse</surname> <given-names>E</given-names></name><name><surname>Linnoila</surname> <given-names>I</given-names></name><name><surname>Liotta</surname> <given-names>L</given-names></name><name><surname>Kelly</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>5958</fpage><lpage>5969</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.17.5958-5969.2001</pub-id><pub-id pub-id-type="pmid">11486034</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>MA</given-names></name><name><surname>Nicolette</surname> <given-names>C</given-names></name><name><surname>Minden</surname> <given-names>A</given-names></name><name><surname>Polverino</surname> <given-names>A</given-names></name><name><surname>Van Aelst</surname> <given-names>L</given-names></name><name><surname>Karin</surname> <given-names>M</given-names></name><name><surname>Wigler</surname> <given-names>MH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Multiple Ras functions can contribute to mammalian cell transformation</article-title><source>Cell</source><volume>80</volume><fpage>533</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90507-3</pub-id><pub-id pub-id-type="pmid">7867061</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>B</given-names></name><name><surname>Guo</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The exocyst at a glance</article-title><source>Journal of Cell Science</source><volume>128</volume><fpage>2957</fpage><lpage>2964</lpage><pub-id pub-id-type="doi">10.1242/jcs.156398</pub-id><pub-id pub-id-type="pmid">26240175</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Wempe</surname> <given-names>MF</given-names></name><name><surname>Guin</surname> <given-names>S</given-names></name><name><surname>Khanna</surname> <given-names>M</given-names></name><name><surname>Meier</surname> <given-names>J</given-names></name><name><surname>Hoffman</surname> <given-names>B</given-names></name><name><surname>Owens</surname> <given-names>C</given-names></name><name><surname>Wysoczynski</surname> <given-names>CL</given-names></name><name><surname>Nitz</surname> <given-names>MD</given-names></name><name><surname>Knabe</surname> <given-names>WE</given-names></name><name><surname>Ahmed</surname> <given-names>M</given-names></name><name><surname>Brautigan</surname> <given-names>DL</given-names></name><name><surname>Paschal</surname> <given-names>BM</given-names></name><name><surname>Schwartz</surname> <given-names>MA</given-names></name><name><surname>Jones</surname> <given-names>DN</given-names></name><name><surname>Ross</surname> <given-names>D</given-names></name><name><surname>Meroueh</surname> <given-names>SO</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Discovery and characterization of small molecules that target the GTPase Ral</article-title><source>Nature</source><volume>515</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature13713</pub-id><pub-id pub-id-type="pmid">25219851</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>C</given-names></name><name><surname>Theodorescu</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RAL GTPases: biology and potential as therapeutic targets in Cancer</article-title><source>Pharmacological Reviews</source><volume>70</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1124/pr.117.014415</pub-id><pub-id pub-id-type="pmid">29196555</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.40474.030</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Musacchio</surname><given-names>Andrea</given-names></name><role>Reviewing Editor</role><aff><institution>Max Planck Institute of Molecular Physiology</institution><country>Germany</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>[Editors’ note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.]</p><p>Thank you for submitting your work entitled &quot;RalB directly triggers invasion downstream oncogenic Ras by mobilizing the Wave complex&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Senior Editor/Reviewing Editor. The reviewers have opted to remain anonymous.</p><p>Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in <italic>eLife</italic>.</p><p>As you will see, all three reviewers recognise the significant potential interest of the work. At the same time, they also identify several limitations of the study. Very concisely, as the detailed reviews are pasted below, the major concerns fall into the following categories:</p><p>1) Concerns that Transwell invasion assay may not be a fair reporter of invasive behaviour of cancer cells.</p><p>2) Concerns that observed effects may reflect possible mislocalization of the probes.</p><p>3) Concerns that sample sizes might be too small to support or deny effects.</p><p>4) Concerns whether the observed effects apply to cancer cells or to normal/physiological context.</p><p>5) Concerns of over-reliance on a single approach without further validation with orthogonal approaches.</p><p>We are afraid that addressing these concerns thoroughly would take in excess of approximately two months, the time limit for revision at <italic>eLife</italic>, and therefore we prefer to return the manuscript to you so that you can decide how to proceed with the manuscript farther.</p><p><italic>Reviewer #1:</italic> </p><p>Zago et al. investigate the mechanisms whereby oncogenic Ras drives invasion. They provide data pointing to RalB as the main driver of invasiveness via the RalGEFs RGL1 and RGL2, independently of MAPK and PI3K. For this, they utilize a novel optogenetic approach, whereby light-controlled local activation of Ral promoted, via its effector exocyst, the recruitment of the Wave Regulatory Complex at the cell leading edge in a Rac1-independent fashion. There, the WRC stimulates protrusion formation. Authors show that illumination-driven Ral activation is sufficient to trigger cell invasion.</p><p>My main criticism for this study is that most of it (if not all) relies in the fanciful, though artificial, optogenetic system to activate Ral. In the complete absence of some alternative approach to verify its results.</p><p>This optogenetic system should simulate Ras-induced activation of Ral. However, in this particular case, the approach taken is rather inconsistent: They use H-RasV12 to transform HEK-HT cells. There, by using Ras effector mutants, they identify the RalGEF pathway as the inductor of invasion. And they utilize this same cellular setting to identify the GEFs RGL1 and RGL2 as the culprits, using a siRNA screen. Then they use the optogenetic system, based on the GEF domain of RGL2, for all subsequent experiments. It is on the Ras &gt; optogenetic system connection where the main shortcomings are found:</p><p>1) For the initial observation they use H-RasV12. However, they use KRas CAAX box to target the optogenetic system to the plasma-membrane. Why do they assume that H-Ras proinvasive signal using RGL1/2 comes from the plasma-membrane? It is well known that H-Ras is found in many membrane systems; why not from endomembranes or endosomes? It could very well be that their optogenetic system, targeted to endomembranes or endosomes evokes a completely different biological outcome. Some attempt to study RGL1/2 sublocalization in H-RasV12-transformed cells would help in this matter.</p><p>2) In this respect, the extent to which the optogenetic system using RGL2 Cdc25 domain resembles &quot;total&quot; RGL2 is doubtful. The Cdc25 domain deprived of its regulatory sequences loses all its &quot;personality&quot;. This reviewer would bet that the same optogenetic system using another Cdc25 domain (even that one of RalGPS1 that does not bind Ras) would yield a very similar outcome (this control must be done). Thus, ultimately, what authors are observing is invasiveness driven by Ral from some insufficiently characterized sublocalization.</p><p>3) Following this line of argument, it would help their case very much if they showed whether overexpression, or inducible expression, of RGL1/2 mimicked the results obtained with the optogenetic system with respect to the exocyst &gt; WRC recruitment.</p><p><italic>Reviewer #2:</italic> </p><p>The manuscript by Zago et al. describes an unexpected central role of RalB in Ras-driven invasion and supports earlier findings about a specific role of RalB, and not of RalA, in cell motility. By using an innovative optogenetic approach they finely dissect the interaction cascade (RalGEF-Ral-Exocyst-WRC) with unprecedented spatial-temporal resolution. The manuscript is generally well written and the experiments appear robustly controlled.</p><p>As a general remark, the authors should discriminate better to which extent their findings apply to a normal physiologic or cancer context, and in the last case, whether they are true for Ras mutant tumor cells, Ras WT tumor cells or both. Unfortunately the fact that part of the experiments are performed in a Ras mutant context and part in a Ras WT context, and that no validation experiments are performed in human cancer cell lines, makes this distinction difficult. I encourage the authors to either validate the role of RalB in invasion in few (Ras mutant and Ras WT) human cancer cell lines (for example by CRISPR knockout of RalB, followed by a Transwell invasion assay), or to mitigate their speculations about the link between RalB and migration in a Ras mutant and tumor context.</p><p>In Figure 1C, the authors show that silencing of RalB, but not RalA, impaired invasion of HEK-HTRasV12 cells of approximately 60%. The authors do not comment on the remaining 40% invasiveness that is not inhibited by RalB suppression. It would be interesting to test whether combined RalA and RalB silencing is able to completely suppress invasion, suggesting that although RalB is the main mediator of invasiveness, RalA is able to take over in the absence of RalB.</p><p>In Figure 3D, the authors do not mention how long the cells were treated with the Rac inhibitor NSC23766. In addition to provide this information, the authors should prove that Rac1 was inhibited in their cells at the dose and time used in their experiment.</p><p>In Figure 5A, the authors show that RalB activation is sufficient to promote invasion by recruiting the WRC via the exocist. At the end of their result description the authors conclude that &quot;since the OptoRal cells do not carry Ras mutations, this experiment shows that RalB activation is able to drive cell invasion even in a wild-type Ras genetic context&quot;. The authors can't make this conclusion, because in their system Ral activation is artificially made independent of Ras activation and mutation status (unless they can quantitatively compare the level of Ral activation following illumination in their OptoRal cells with the levels of endogenous Ral activation in the presence of WT or mutant Ras).</p><p>In Figure 5A, the authors should include OptoRal and OptoControl cells (without iRFP-Abi1) to show if invasion is increased after illumination-induced Ral activation in the presence of endogenous levels of Abi1, or if overexpression is needed.</p><p><italic>Reviewer #3:</italic> </p><p>In this manuscript Zago et al. report that Ral activation causes recruitment of the Scar/WAVE complex via the exocyst complex. The authors describe the development of an elegant novel optogenetics approach to recruit a RalGEF to the plasma membrane upon blue light illumination thereby activating Ral proteins at this location. They report that this causes recruitment of the Scar/WAVE complex and causes consequently membrane protrusion independent of Rac activity. They further claim that active Ras induced cell invasion depends on Ral but not MAPK or PI3K activity and is mediated by RalGEFs RGL1/2. Finally, they suggest that Ral mediated increase in cell invasion is mediated by the exocyst recruiting the Scar/WAVE complex.</p><p>This is potentially a very exciting story: Even though many regulatory mechanisms of the Scar/WAVE complex are known, it is still not clear how its activity is controlled in time and space during lamellipodia protrusion and cell migration and invasion. In general, the study is done with great care and well controlled. Therefore, I would be willing to support the publication of this manuscript in <italic>eLife</italic> if my major concerns are adequately addressed:</p><p>1) Transwell invasion assays used in Figure 1 and 5 have inherent shortcomings: It is an endpoint analysis which does not allow visualization of the invasion. Thus, it does not control for a defect or increase in adhesion and these could be interpreted as a decrease or increase in invasion. Inverted invasion assays are more reliably controlled in vitro invasion assays.</p><p>2) In Figure 1B: It is quite a big statement that Ras driven invasion is mediated by Ral from this one Transwell assay. This needs to be backed up by data from other assays for example, inverted invasion assays using knockdown, MAPK pathway inhibitors etc. The spread of the mean between individual experiments is huge and does not give confidence in the reliability of the Transwell experiment.</p><p>3) Figure 4B, D: Why does the iRFP-Abi in the OptoRal cells does not localise to the leading edge of cells as one would expect if it is incorporated into the Scar/WAVE complex? This is seen for the iRFP-Abi in the OptoControl cells. An increase of the iRFP-Abi in the OptoRal cells at the leading edge and not just at the membrane underneath the cell would increase confidence that RalB-exocyst activation contributes to a physiological recruitment of the WRC to the leading edge of cells. Could you activate a smaller area only at the leading edge of cells with blue light? Alternatively, you could use mesenchymal cells that form larger lamellipodia. In addition to Abi another component of the Scar/WAVE besides Abi should be imaged since Abi can interact with N-WASP independently of the Scar/WAVE complex.</p><p>4) For some of the experiments more appropriate statistics should be used (see below).</p><p>Figure 1B-E: Repeated t-test is inappropriate. The appropriate statistics to compare several groups is One-way ANOVA.</p><p>Figure 1C: Please show a western blot.</p><p>Supplementary Figure 1A-B: The information for the statistics used is missing.</p><p>Figure 1C, E: It is more appropriate to normalise the control siRNA values in a way to retain the SD and not to arbitrarily set them to a fixed value of 100%. This will influence your statistics in an inappropriate way. This can be done in PRISM using the normalise function and setting the 0% to 0 and 100% to the mean of your control.</p><p>Figure 1E: RalGPS2 has a big spread between the means whereas RGL1/2 have a small spread. Doing more repeats for RalGPS2 may also reveal a significant reduction. Therefore, it is premature to conclude that the Ras mediated activation of RalB is mediated only by RGL1/2.</p><p>Video 2 appears to be the same as Video 1. Is this a mistake?</p><p>Figure 2B: Is this increase in protrusion formation dependent on Ral activation? Use CRY2-mCherry as control. This should not lead to protrusion formation. I guess this was done in Figure 3D? Does OptoControl stands for CRY2-mCherry control?</p><p>Figure 2E: How reliable is the Sec5GBD-iRFP or PakGBD recruitment as a tool to measure Ral and Rac activity? This should be confirmed using a FRET biosensor or pulldown assays of active Rac or RalB.</p><p>Figure 1—figure supplement 1C: What is the extra band at 110 kDa in the mCherry blot that shows up in both Opto control and Ral lysates?</p><p>Figure 3: The Recruitment Edge dynamics and MATLAB based segmentation method needs to be described better since it is unpublished unless the cited in press paper is available on a preprint server.</p><p>Figure 3D: Two-way ANOVA would be the more appropriate statistics here instead of repeated t-tests since several groups are compared. The vehicle control for the Rac inhibitor is missing.</p><p>Figure 5A: Two-way ANOVA would be the more appropriate statistics here instead of repeated t-tests since several groups are compared.</p><p>[Editors’ note: what now follows is the decision letter after the authors submitted for further consideration.]</p><p>Thank you for resubmitting your work entitled &quot;RalB directly triggers invasion downstream Ras by mobilizing the Wave complex&quot; for further consideration at <italic>eLife</italic>. Your revised article has been favorably evaluated by Andrea Musacchio as the Senior/Reviewing Editor, and two reviewers.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p><italic>Reviewer #1:</italic> </p><p>The authors have re-written the study and provided new data to generate a coherent and convincing case.</p><p>A minor experiment would be necessary to round up the whole story: authors speculate that the &quot;light-controlled stimulation of cell protrusions is essentially due to the activation of endogenous RalB, rather than RalA&quot;. In order to prove this beyond doubt, and to match this data with that shown in Figure 5C for HEK-RasV12 cells, the OptoRal light-controlled stimulation of cell protrusions should be performed using siRNAs for RalA and B.</p><p><italic>Reviewer #2:</italic> </p><p>The new version of the manuscript by Zago et al. maintains the merit to address the poorly explored role of Ral proteins as downstream Ras effectors, in particular in cell invasion. The authors apply the innovative optogenetic approach to finely dissect the molecular cascade that links Ras activation to invasion in their specific cellular model.</p><p>The new version of the manuscript is substantially improved, both with respect to the clarity of the results presentation and the consistency of the conclusions drawn by the authors.</p><p>The additional experiments helped making the data more robust and clarifying that the RalGEF-Ral-Exocyst-WRC cascade appears relevant in the tumor context although independent of Ras mutational status.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.40474.031</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>[Editors’ note: the author responses to the first round of peer review follow.]</p><p>We thank the three reviewers for their constructive criticisms that helped to direct our efforts to improve the quality of our paper.</p><p>A consistent amount of new data was included for a total of 10 new panels in the main figures, and 9 new panels in the supplementary figures.</p><p>In particular, we now show clinical data from breast cancer tissue samples, thanks to a fruitful collaboration with the pathology department of Curie Hospital (and consequently a few extra authors). These new data show a correlation between expression at protein level of RalB (and not RalA) and disease progression. This is the first evidence of an implication of Ral pathway in breast cancers, and complements the available literature on the role of Ral in other human cancers, including lung, colon, pancreas, prostate, melanoma.</p><p>In such broader human health perspective, it should become more obvious the added value of optogenetics in Ral signaling field. We could move from correlations to causality, 1) demonstrating the sufficiency of RalB activation to trigger invasion, and 2) identifying the underlying molecular mechanisms.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>[…] My main criticism for this study is that most of it (if not all) relies in the fanciful, though artificial, optogenetic system to activate Ral. In the complete absence of some alternative approach to verify its results.</p><p>This optogenetic system should simulate Ras-induced activation of Ral. However, in this particular case, the approach taken is rather inconsistent: They use H-RasV12 to transform HEK-HT cells. There, by using Ras effector mutants, they identify the RalGEF pathway as the inductor of invasion. And they utilize this same cellular setting to identify the GEFs RGL1 and RGL2 as the culprits, using a siRNA screen. Then they use the optogenetic system, based on the GEF domain of RGL2, for all subsequent experiments. It is on the Ras &gt; optogenetic system connection where the main shortcomings are found:</p></disp-quote><p>We realize that unfortunately the original presentation structure lacked clarity and produced several misunderstandings. We now changed the order as follows.</p><p>First, we better introduce the previous literature supporting a role for RalB role in human cancer invasion (Introduction, second paragraph), and we clearly state that the optogenetic approach is a tool to study the underlying molecular mechanisms (subsection “Optogenetic control for selective activation of Ral proteins”, first paragraph). Of course, optogenetic Ral activation must be performed in a wt Ras context, in which Ral is not abnormally stimulated; this is why we chose the HEK-HT cell model. We engineered our constructs in a way to activate Ral at the plasma-membrane because the literature indicates that Ral oncogenic signaling emanates at least in part from the plasma-membrane: the membrane-targeted murine RalGEF Rlf-CAAX transforms HEK-HT and BJ-HT human cells (Hamad et al., 2002; Lim et al., 2005); the expression of membrane-targeted human RalGDS-CAAX promotes metastasis of murine 3T3 cells in a tail vein injection assay (Ward et al., 2001).</p><p>Second, we describe the optogenetic experiments and conclusions on the cause-effect link between Ral activation (at the plasma-membrane), WRC recruitment, protrusion formation, and invasion (now adding results from a second in vitro invasion assay, new Figure 5B, 5D).</p><p>Third, we evaluate the relative contributions of Ral, MAPK and PI3K pathways, in an oncogenic Ras context, the HEK-HT-H-RasV12 cell model, finding that RalB pathway appears to be the major driver of Ras-dependent invasiveness, as shown by the V12G37 mutant and by pharmacological inhibitors (new Figure 5F).</p><p>Fourth, by a siRNA screen, we identified RGL1 and RGL2 as the missing molecular link between H-RasV12 and RalB for invasion. Consistently, we now show that oncogenic Ras drives recruitment of endogenous RGL2 and RalB at the cell plasma-membrane (new Figure 6B, 6C).</p><p>Fifth, we now add clinical data from breast cancer tissue samples, showing that RalB protein expression increases in a manner consistent with cancer progression (normal &lt; in situ &lt; invasive &lt; metastatic tissues) (new Figure 7).</p><p>We note that while the application of optogenetics led us to robust mechanistic conclusions, in the revised version a conspicuous amount of the reported results (3 out of 7 figures) do not rely on the optogenetic system.</p><disp-quote content-type="editor-comment"><p>1) For the initial observation they use H-RasV12. However, they use KRas CAAX box to target the optogenetic system to the plasma-membrane. Why do they assume that H-Ras proinvasive signal using RGL1/2 comes from the plasma-membrane? It is well known that H-Ras is found in many membrane systems; why not from endomembranes or endosomes? It could very well be that their optogenetic system, targeted to endomembranes or endosomes evokes a completely different biological outcome. Some attempt to study RGL1/2 sublocalization in H-RasV12-transformed cells would help in this matter.</p></disp-quote><p>We totally agree with the reviewer that optogenetic activation of Ral at endomembranes might lead to different biological outcomes, taking into account for example the crucial role of RalB in autophagy. Indeed, our future efforts go towards this direction. The point of this paper is that activation of Ral at plasma-membrane leads to invasiveness, without excluding other outputs, depending or not on the location of Ral activity.</p><p>As proposed by the reviewer, we studied RGL2 (and RalB) subcellular localization in HEK-HT versus H-RasV12 transformed cells: oncogenic Ras drives recruitment of endogenous RGL2 and RalB at the cell plasma-membrane (new Figure 6B, 6C), thus supporting the relevance of our choice to optogenetically activate Ral at the plasma-membrane.</p><disp-quote content-type="editor-comment"><p>2) In this respect, the extent to which the optogenetic system using RGL2 Cdc25 domain resembles &quot;total&quot; RGL2 is doubtful. The Cdc25 domain deprived of its regulatory sequences loses all its &quot;personality&quot;. This reviewer would bet that the same optogenetic system using another Cdc25 domain (even that one of RalGPS1 that does not bind Ras) would yield a very similar outcome (this control must be done). Thus, ultimately, what authors are observing is invasiveness driven by Ral from some insufficiently characterized sublocalization.</p></disp-quote><p>There is a big misunderstanding on this point. We never meant to mimic RGL2 signaling using just its catalytic RalGEF Cdc25-like domain. We totally agree with the reviewer that very likely any other catalytic RalGEF Cdc25-like domain would yield a very similar outcome, i.e. protrusion and invasion. The choice of RGL2 was motivated by the fact that its minimal RalGEF Cdc25-like domain has been well characterized biochemically (Ferro et al., 2008), not because it was a hit in our screen. To avoid this misinterpretation we now present the results of the RalGEFs screen after the results of optogenetics. In fact, we exploited a minimal RalGEF domain and removed on purpose the regulatory sequences of RGL2, in order to assess the effects of only Ral activation at the plasma membrane, without stimulation of any other pathway. The fact that we see invasiveness just with a RalGEF domain shows that Ral activation per se (at the plasma-membrane) is sufficient for this outcome.</p><disp-quote content-type="editor-comment"><p>3) Following this line of argument, it would help their case very much if they showed whether overexpression, or inducible expression, of RGL1/2 mimicked the results obtained with the optogenetic system with respect to the exocyst &gt; WRC recruitment.</p></disp-quote><p>We hope that the above explanations clarified the fact that our optogenetic system (at the plasma-membrane, with a minimal RalGEF Cdc25 domain) allows indeed the fine control of when and where we activate endogenous Ral, and for this reason it is superior to an overexpression approach of full-length RGL2 which might lead to uncontrolled/mislocalized Ral hyperactivation and/or dominant negative effects. Any experimental approach is artificial, but optogenetics has the great advantage to discriminate between ‘before’ and ‘after’ the perturbation, in a time scale of a few seconds.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>The manuscript by Zago et al. describes an unexpected central role of RalB in Ras-driven invasion and supports earlier findings about a specific role of RalB, and not of RalA, in cell motility. By using an innovative optogenetic approach they finely dissect the interaction cascade (RalGEF-Ral-Exocyst-WRC) with unprecedented spatial-temporal resolution. The manuscript is generally well written and the experiments appear robustly controlled.</p><p>As a general remark, the authors should discriminate better to which extent their findings apply to a normal physiologic or cancer context, and in the last case, whether they are true for Ras mutant tumor cells, Ras WT tumor cells or both. Unfortunately the fact that part of the experiments are performed in a Ras mutant context and part in a Ras WT context, and that no validation experiments are performed in human cancer cell lines, makes this distinction difficult. I encourage the authors to either validate the role of RalB in invasion in few (Ras mutant and Ras WT) human cancer cell lines (for example by CRISPR knockout of RalB, followed by a Transwell invasion assay), or to mitigate their speculations about the link between RalB and migration in a Ras mutant and tumor context.</p></disp-quote><p>In the revised version, it is now clear that our findings apply to cancer context. We better introduce the previous literature supporting a role for Ral pathway in various human cancers, with a specific function for RalB in invasion (Introduction, second paragraph). Moreover, we add original data on Ral protein expression in breast cancer tissue samples, supporting for the first time a potential implication of RalB in breast cancer progression (new Figure 7 and Figure 7—figure supplement 1).</p><p>The requirement of RalB for Transwell invasion has been previously validated by shRNA knock-down by the group of Chris Counter in seven out of nine K-Ras mutated human pancreatic cancer cell lines (Lim et al., 2006).</p><p>We analyzed the effect of RalB silencing by siRNA in two invasive human breast cancer cell lines: MDA-MB-231 (carrying the K-RasG13D mutation) and BT549 (Ras wild-type). RalB was required for invasion in both breast cancer cell models (new Figure 7D), suggesting that RalB might play a role in invasion not only down-stream mutated Ras, but also in Ras wild-type contexts.</p><disp-quote content-type="editor-comment"><p>In Figure 1C, the authors show that silencing of RalB, but not RalA, impaired invasion of HEK-HTRasV12 cells of approximately 60%. The authors do not comment on the remaining 40% invasiveness that is not inhibited by RalB suppression. It would be interesting to test whether combined RalA and RalB silencing is able to completely suppress invasion, suggesting that although RalB is the main mediator of invasiveness, RalA is able to take over in the absence of RalB.</p></disp-quote><p>We performed this experiment and we added the results in Figure 5C. The silencing of both RalB and RalA reached up to 90% invasion inhibition, more than the silencing of RalB alone (60%). This indicates that even though RalA is dispensable for invasion, it might partially compensate when RalB is absent, as correctly anticipated by the reviewer (subsection “Ras-driven cancer invasion requires activation of RalB via RGL1 and RGL2”, second paragraph).</p><disp-quote content-type="editor-comment"><p>In Figure 3D, the authors do not mention how long the cells were treated with the Rac inhibitor NSC23766. In addition to provide this information, the authors should prove that Rac1 was inhibited in their cells at the dose and time used in their experiment.</p></disp-quote><p>The treatment with NSC23766 at 100 mM was started 1 hr before the acquisitions and maintained during the entire experiment; this is now mentioned in the legend of Figure 2D. OptoRal cells, treated at the same dose and time, were subjected to a pull-down assay, showing an inhibition of approximately 50% of the active Rac1-GTP amount (new Figure 2—figure supplement 2C).</p><disp-quote content-type="editor-comment"><p>In Figure 5A, the authors show that RalB activation is sufficient to promote invasion by recruiting the WRC via the exocist. At the end of their result description the authors conclude that &quot;since the OptoRal cells do not carry Ras mutations, this experiment shows that RalB activation is able to drive cell invasion even in a wild-type Ras genetic context&quot;. The authors can't make this conclusion, because in their system Ral activation is artificially made independent of Ras activation and mutation status (unless they can quantitatively compare the level of Ral activation following illumination in their OptoRal cells with the levels of endogenous Ral activation in the presence of WT or mutant Ras).</p></disp-quote><p>The sentence was removed. We changed the chapter title to “Activation of Ral-exocyst-WRC axis promote invasion of non-transformed cells”.</p><disp-quote content-type="editor-comment"><p>In Figure 5A, the authors should include OptoRal and OptoControl cells (without iRFP-Abi1) to show if invasion is increased after illumination-induced Ral activation in the presence of endogenous levels of Abi1, or if overexpression is needed.</p><p>The experiment was done leading to the expected result (new Figure 4A).</p><p>Reviewer #3:</p><p>[…] 1) Transwell invasion assays used in Figure 1 and 5 have inherent shortcomings: It is an endpoint analysis which does not allow visualization of the invasion. Thus, it does not control for a defect or increase in adhesion and these could be interpreted as a decrease or increase in invasion. Inverted invasion assays are more reliably controlled in vitro invasion assays.</p></disp-quote><p>Following the recommendation of reviewer #3, we performed several Inverted invasion assays, using 3D collagen I gels (detailed protocol in Materials and methods section), which nicely complemented the standard Transwell assays with a matrigel layer.</p><p>We confirmed that the expression of H-RasV12 promotes invasion of HEK-HT cells also in a 3D collagen gel (new Figure 5B), and that RalB is required for this Ras-driven invasiveness (new Figure 5D).</p><disp-quote content-type="editor-comment"><p>2) In Figure 1B: It is quite a big statement that Ras driven invasion is mediated by Ral from this one Transwell assay. This needs to be backed up by data from other assays for example, inverted invasion assays using knockdown, MAPK pathway inhibitors etc. The spread of the mean between individual experiments is huge and does not give confidence in the reliability of the Transwell experiment.</p></disp-quote><p>We believe that the expanded version of Figure 5 (previous Figure 1A, B, C) better support our conclusion that RalB contribution appears to be more important than that of MAPK and PI3K pathways, at least in our genetically controlled cell model.</p><p>The inhibitory impact of RalB silencing on HEK-HT-H-RasV12 invasiveness is now shown by Transwell invasion assay (Figure 5C) and by Inverted invasion assay (new Figure 5D).</p><p>The previous results with the RasV12G37 mutant (Figure 5E) are not backed up by new data (new Figure 5F) using Trametinib and PIK90 to very efficiently inhibit MAPK and PI3K pathways, respectively. The new results clearly show that HEK-HT-RasV12 cells are still able to invade even when MAPK or PI3K pathways are very efficiently inhibited by the drugs, as assessed by Transwell invasion assay.</p><p>We tried a similar drug approach using the Inverted invasion assay. However, since this assay requires much longer time than the Transwell invasion assay (4 days instead of 6 hrs), the strong cytostatic effect of Trametinib and PIK90 on this time scale is a very important bias. Moreover, we observed that the morphology of the cells in the collagen gel was greatly impacted by 4 days treatments. The standard deviations were huge and no significant statistical differences could be identified without versus with treatments (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>).</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.40474.028</object-id><label>Author response image 1.</label><caption/><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-40474-resp-fig1-v3"/></fig><disp-quote content-type="editor-comment"><p>3) Figure 4B, D: Why does the iRFP-Abi in the OptoRal cells does not localise to the leading edge of cells as one would expect if it is incorporated into the Scar/WAVE complex? This is seen for the iRFP-Abi in the OptoControl cells. An increase of the iRFP-Abi in the OptoRal cells at the leading edge and not just at the membrane underneath the cell would increase confidence that RalB-exocyst activation contributes to a physiological recruitment of the WRC to the leading edge of cells. Could you activate a smaller area only at the leading edge of cells with blue light? Alternatively, you could use mesenchymal cells that form larger lamellipodia.</p></disp-quote><p>The iRFP-Abi does always localize at the protruding leading edges. However, it is sometime tricky to show this sharp localization because of a combination of reasons: i) the leading edge is above the ventral plan which is captured by TIRF; ii) edge movements and Abi1 recruitment present very fast cycling dynamics (protrusion-retraction alternation closely correlating with on-off Abi1 recruitment); iii) iRFP photo-bleaching does occur. Illumination triggers WRC recruitment both at the leading edge and at the ventral side.</p><p>We now provide a representative OptoRal cell with a more obvious localization of iRFP-Abi at the leading edge (new Figure 3B and new Video 5). For clarity, we also changed the representative OptoControl (new Figure 3C and new Video 6). In these two cells, iRFP ‘edge’ recruitment was quantified by using an automated method that measures the maximum fluorescent intensity at the edge (width of 1.12 µm) (Paul-Gilloteaux et al., 2018): the resulting heat maps show a dynamic edge fluorescence appearing upon illumination in OptoRal cell (Figure 3B, left) but not in OptoControl cell (Figure 3C, left).</p><p>For measurements on several cells and statistical analysis, we chose to quantify iRFP-Abi recruitment at the ‘ventral’ membrane because this was the location where TIRF measurements were precise. HEK-HT cells have pretty large lamellipodia.</p><disp-quote content-type="editor-comment"><p>In addition to Abi another component of the Scar/WAVE besides Abi should be imaged since Abi can interact with N-WASP independently of the Scar/WAVE complex.</p></disp-quote><p>The gel filtration experiments reported in Figure 3—figure supplement 1 indicate that the vast majority (~ 80%) of the exogenous iRFP-Abi co-eluted with the Cyfip subunit in fractions 16-18, corresponding to the expected molecular weight of whole WRC complex (~ 400 kDa). Consequently, the imaged iRFP signal mainly reports the localization of the whole WRC complex.</p><p>Moreover, in our experience, it is technically very difficult to use fluorescent fusion with other subunits of WRC complex; for example, GFP-Wave expression seems to produce dominant negative effects.</p><disp-quote content-type="editor-comment"><p>4) For some of the experiments more appropriate statistics should be used (see below).</p></disp-quote><p>As indicated in Statistics paragraph of Materials and methods, we now proceed as follow. “Comparisons between two groups were assessed using Student t-test. Comparisons between more than two groups were assessed using one-way ANOVA test. Comparisons between paired data were assessed using Wilcoxon signed-rank test.”</p><p>See below specific answers.</p><disp-quote content-type="editor-comment"><p>Figure 1B-E: Repeated t-test is inappropriate. The appropriate statistics to compare several groups is One-way ANOVA.</p></disp-quote><p>We confirmed the conclusions by applying one-way ANOVA statistical test.</p><disp-quote content-type="editor-comment"><p>Figure 1C: Please show a western blot.</p><p>A representative western blot is presented as supplementary Figure 6A.</p><p>Supplementary Figure 1A-B: The information for the statistics used is missing.</p></disp-quote><p>For clarity, since the western blots were highly reproducible, we now show only representative western blots for which we indicate the quantifications below the relevant panels.</p><disp-quote content-type="editor-comment"><p>Figure 1C, E: It is more appropriate to normalise the control siRNA values in a way to retain the SD and not to arbitrarily set them to a fixed value of 100%. This will influence your statistics in an inappropriate way. This can be done in PRISM using the normalise function and setting the 0% to 0 and 100% to the mean of your control.</p><p>We thank the reviewer for this useful PRISM tip. We normalized as suggested.</p><p>Figure 1E: RalGPS2 has a big spread between the means whereas RGL1/2 have a small spread. Doing more repeats for RalGPS2 may also reveal a significant reduction. Therefore, it is premature to conclude that the Ras mediated activation of RalB is mediated only by RGL1/2.</p></disp-quote><p>We mitigated our conclusions for RalGPS2: “RalGPS2 silencing showed a potential inhibitory effect, even though statistically not significant”.</p><disp-quote content-type="editor-comment"><p>Video 2 appears to be the same as Video 1. Is this a mistake?</p></disp-quote><p>Yes, it was an uploading mistake for which we apologize. The video was changed.</p><disp-quote content-type="editor-comment"><p>Figure 2B: Is this increase in protrusion formation dependent on Ral activation? Use CRY2-mCherry as control. This should not lead to protrusion formation. I guess this was done in Figure 3D? Does OptoControl stands for CRY2-mCherry control?</p></disp-quote><p>Yes, this was done in Figure 3C, 3D, now Figure 2C, 2D. Yes, OptoControl stands for CRY2-mCherry control. We now make this point clearer by specifying the genetics of OptoRal and OptoControl cells also in panels B and C of Figure 2, in addition to the main text (subsection “Optogenetic control for selective activation of Ral proteins”, first paragraph).</p><disp-quote content-type="editor-comment"><p>Figure 2E: How reliable is the Sec5GBD-iRFP or PakGBD recruitment as a tool to measure Ral and Rac activity? This should be confirmed using a FRET biosensor or pulldown assays of active Rac or RalB.</p></disp-quote><p>Recruitment of GBD domains is a widely used strategy to follow GTPase activities by live imaging. PakGBD-iRFP was used in a previous work (Valon et al., 2015). Sec5GBD-iRFP was cloned for this work, using a Sec5GBD domain (aa 5-97) previously validated for Ral pull-down assays.</p><p>We agree that it is important to be sure that our approach activates RalB. We performed additional experiments: both pull-down assays (new Figure 2—figure supplement 1A) and a RalB FRET biosensor indicated (new Figure 2—figure supplement 1B) that light stimulates RalB activity in our OptoRal cells.</p><disp-quote content-type="editor-comment"><p>Figure 1—figure supplement 1C: What is the extra band at 110 kDa in the mCherry blot that shows up in both Opto control and Ral lysates?</p></disp-quote><p>The band is a non-specific band recognized by anti-Cherry antibodies. The band was present also in anti-Cherry western blot from HEK-HT lysates. This is now mentioned in the legend.</p><disp-quote content-type="editor-comment"><p>Figure 3: The Recruitment Edge dynamics and MATLAB based segmentation method needs to be described better since it is unpublished unless the cited in press paper is available on a preprint server.</p><p>The paper is now published and the corresponding reference was added: Paul-Gilloteaux et al., 2018.</p><p>Figure 3D: Two-way ANOVA would be the more appropriate statistics here instead of repeated t-tests since several groups are compared. The vehicle control for the Rac inhibitor is missing.</p></disp-quote><p>It is true that in this experiment we have two variables (light/dark and cellular condition). However, for our purposes, we are interested in comparing only the effect of changing light/dark on each cellular condition, so we test only the light/dark variable. In addition, the measurements were paired: same cell pre and post illumination. For these reasons we believe that the most appropriate test is Wilcoxon signed-rank test for paired data.</p><disp-quote content-type="editor-comment"><p>Moreover, following the suggestion of reviewer #2, we now also compare the difference in the delta velocity pre and post illumination in the presence or absence of the Rac inhibitor and we report in the legend that there is no difference (Student t-test, since we are comparing two groups: deltas in presence and deltas in absence of the Rac inhibitor). The Rac inhibitor was dissolved in water.</p><p>Figure 5A: Two-way ANOVA would be the more appropriate statistics here instead of repeated t-tests since several groups are compared.</p></disp-quote><p>It is true that in this experiment we have two variables (light/dark and cellular condition). However, for our purposes, we are interested in comparing each variable independently. We want to test i) the effect of changing light/dark variable on each cellular condition, ii) the effect of changing cellular condition variable in dark, and iii) the effect of changing cellular condition variable in light. We never compare two groups in which both conditions are changing, for example we do not test OptoControl dark versus OptoRal light. For these reasons we believe that the most appropriate test is One-way ANOVA.</p><p>[Editors' note: the author responses to the re-review follow.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:</p><p>Reviewer #1:</p><p>The authors have re-written the study and provided new data to generate a coherent and convincing case.</p><p>A minor experiment would be necessary to round up the whole story: authors speculate that the &quot;light-controlled stimulation of cell protrusions is essentially due to the activation of endogenous RalB, rather than RalA&quot;. In order to prove this beyond doubt, and to match this data with that shown in Figure 5C for HEK-RasV12 cells, the OptoRal light-controlled stimulation of cell protrusions should be performed using siRNAs for RalA and B.</p></disp-quote><p>As recommended by reviewer #1, we performed OptoRal light-controlled stimulation of cell protrusions in cells transfected with siRNAs targeting RalA or RalB.</p><p>RalB-depleted cells, but not RalA depleted cells, were impaired in protrusions formation, proving that light-controlled stimulation of protrusions is essentially due to activation of endogenous RalB, rather than RalA (new of Figure 2E, new Figure 2—figure supplement 3D).</p></body></sub-article></article>